[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 327
1. Rodríguez-Antona C, Leskelä S, Zajac M, Cuadros M, Alvés J, Moneo MV, Martín C, Cigudosa JC, Carnero A, Robledo M, Benitez J, Martínez-Delgado B: Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood; 2007 Nov 1;110(9):3345-51
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCLs) are aggressive tumors in which the current therapy based on multiagent chemotherapy is not successful.
  • Since cytochrome P450 3A subfamily (CYP3A) enzymes are involved in the inactivation of chemotherapy drugs, we hypothesized that CYP3A and P-glycoprotein (MDR1) expression in these lymphomas could result in a poor clinical response.
  • We measured tumoral CYP3A and MDR1 mRNA content in 44 T-cell lymphomas, finding a large variation in CYP3A expression.
  • Multiplex polymerase chain reaction (PCR) analysis and fluorescence in situ hybridization (FISH) analysis showed genomic gains affecting CYP3A and MDR1 genes in T-cell lines and primary tumors, suggesting that this could be the mechanism underlying the tumoral expression variation.
  • To test whether the tumoral expression of CYP3A and/or MDR1 could influence PTCL treatment outcome, their expression levels were compared with the clinical response and survival of the patients, finding that a high tumoral expression of CYP3A4 was significantly associated with a lower complete remission rate.
  • This was further investigated with cell lines stably expressing CYP3A4 that exhibited an increased resistance to doxorubicin and etoposide.
  • In conclusion, a high CYP3A4 tumoral expression could be useful to predict poor response to the standard PTCL chemotherapy; in these cases alternative chemotherapy combinations or doses should be explored.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytochrome P-450 Enzyme System / genetics. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 7. Cytochrome P-450 CYP3A. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm / genetics. Etoposide / therapeutic use. Gene Duplication. Gene Expression. Gene Expression Regulation, Neoplastic. Humans. Jurkat Cells. P-Glycoprotein / genetics. P-Glycoproteins. Prognosis. Survival Analysis. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634410.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


2. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E, GEL/TAMO Spanish Group: High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica; 2003 Dec;88(12):1372-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
  • BACKGROUND AND OBJECTIVES: Patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis.
  • However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival when treated with high dose chemotherapy and autologous stem cell transplantation (HDC/ASCT).
  • The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL).
  • DESIGN AND METHODS: We retrospectively evaluated the efficacy of ASCT in 35 patients with PTCL from the GEL-TAMO registry, who did not achieve a CR to standard induction chemotherapy regimens for aggressive NHL.
  • Thirty-one patients underwent transplantation after achieving a partial response (PR) and 4 patients were non-responders.
  • RESULTS: Following HDC/ASCT, 23 (66%) of the patients achieved a CR, 4 (11%) a PR and in 7 (20%) cases the transplant failed.
  • One patient was not evaluated because of early toxic death.
  • With a median follow-up of the survivors of 37.5 months, 18 patients (51%) are alive and 15 patients (43%) are free of disease.
  • Transplant-related mortality rate at 100 days was 11% and at 5 years the probabilities of survival, freedom from progression and disease-free survival for complete responders were 37%, 36% and 55% respectively.
  • Pre-transplant lactate-dehydrogenase level, age-adjusted International Prognostic Index (aa-IPI) and tumor score correlated with survival.
  • INTERPRETATION AND CONCLUSIONS: One third of the patients with PTCL who fail to achieve CR to the first chemotherapeutic regimen can be rescued with HDC/ASCT.
  • Pre-transplant values of IPI and tumor score risk systems for aggressive lymphomas were useful to predict subsequent survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Peripheral Blood Stem Cell Transplantation. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies. Severity of Illness Index. Spain. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14687990.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


3. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M: Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood; 2010 Nov 4;116(18):3418-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
  • To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343 patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • Two hundred eighty-nine patients belonged to 1 of the 4 major T-cell lymphoma subtypes: anaplastic large cell lymphoma (ALCL), anaplastic large cell lymphoma kinase (ALK)-positive (n = 78); ALCL, ALK-negative (n = 113); peripheral T-cell lymphoma, unspecified (PTCLU; n = 70); and angioimmunoblastic T-cell lymphoma (AITL; n = 28).
  • Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP).
  • The International Prognostic Index (IPI) was effective in defining risk groups with significantly different outcomes.
  • In patients > 60 years 6 courses of CHOP administered every 3 weeks remains the standard therapy.
  • Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Killer Cells, Natural / pathology. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Prognosis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult


Advertisement
4. Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S: EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood; 2008 Aug 15;112(4):1039-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
  • Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma.
  • As part of an ongoing phase 2 trial in which we recently treated 20 patients with 8 cycles of CHOP every 2 weeks with 3 additional doses of 30 mg alemtuzumab per cycle, we observed the development of Epstein-Barr virus (EBV)-positive lymphoproliferative disease, after completion of the immunochemotherapy in 3 patients with peripheral T-cell lymphoma.
  • Because the occurrence of EBV-positive lymphoproliferative disease is rare after alemtuzumab monotherapy, such as is given for chronic lymphocytic leukemia, we think that early reporting of this potential side effect is warranted.
  • It may be caused by intrinsic T-cell defects in patients with T-cell lymphoma, or by the combination of alemtuzumab with CHOP chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / administration & dosage. Antibodies, Neoplasm / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpesvirus 4, Human. Lymphoma / chemically induced. Lymphoma / virology. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502831.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol; 2001 Sep 01;19(17):3766-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
  • PURPOSE: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy.
  • PATIENTS AND METHODS: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D.
  • A Pretransplant International Prognostic Index score of < or = 1 indicated a superior survival rate (P = .036) but not an improved PFS rate.
  • A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease.
  • CONCLUSION: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin's lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients.
  • Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Transplantation, Autologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Mar 1;20(5):1426-7 [11870192.001]
  • (PMID = 11533100.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


6. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood; 2007 Oct 1;110(7):2316-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
  • To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses.
  • Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease.
  • At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR.
  • So far, 13 are disease-free, with an overall median duration of response of 11 months.
  • (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications.
  • This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Societies, Medical
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Glycoproteins / metabolism. Humans. Italy. Kaplan-Meier Estimate. Middle Aged. Multicenter Studies as Topic. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581918.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Sakata K, Fuwa N, Kodaira T, Aratani K, Ikeda H, Takagi M, Nishio M, Satoh M, Nakamura S, Satoh H, Hareyama M: Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol; 2006 May;79(2):179-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification.
  • BACKGROUND AND PURPOSE: This study was conducted to analyze the influence of radiotherapy doses and chemotherapy doses and clinical parameters on in-field disease control in order to assess the optimal radiation doses for treatment of mature T/NK-cell lymphomas according to the newly proposed WHO classification.
  • PATIENTS AND METHODS: Subjects consisted of 62 patients with mature T/NK-cell lymphomas treated with radiotherapy at four Japanese institutions between 1983 and 2002.
  • We reevaluated all histopathological specimens of non-Hodgkin's lymphomas (NHL), using the WHO classification.
  • Radiation therapy was usually delivered to the involved field.
  • The majority of patients also received adriamycin-based chemotherapy such as CHOP, modified CHOP, or more intensive chemotherapy.
  • RESULTS: There were no significant differences in radiosensitivity among subtypes of mature T/NK-cell lymphomas, at least between extranodal NK/T-cell lymphomas, nasal type and peripheral T-cell lymphomas, unspecified.
  • There was a radiation dose-response in non-bulky mature T/NK-cell lymphomas, indicating that radiation doses of more than 52 Gy may be required to obtain in-field control.
  • However, it was difficult to obtain local control of bulky T-cell lymphomas, even with high doses of irradiation.
  • CONCLUSIONS: Mature T/NK-cell lymphomas were more radioresistant than B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL).
  • The chemotherapy including adriamycin did not improve the in-field control of mature T/NK-cell lymphomas.
  • These results were obtained by using non-randomized data and the significance of these results is limited by bias in data.
  • However, our results suggest that the treatment strategy which is usually used for DLBCL, that is, a combined modality of CHOP and around 40 Gy of radiotherapy, may not be sufficiently effective for mature T/NK-cell lymphomas.
  • [MeSH-major] Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644044.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


8. Dreger P, Laport GG: Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. Biol Blood Marrow Transplant; 2008 Jan;14(1 Suppl 1):100-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
  • Mantle cell lymphoma (MCL) and peripheral T cell lymphoma (PTCL) are distinct lymphoma subtypes that each comprise about approximately 10% of the non-Hodgkin lymphomas.
  • Although both subtypes are characterized by high remission rates to frontline chemotherapy, the prognosis is generally poor because of inevitable relapse within 1-2 years or less, depending on the specific histology.
  • Patients with MCL who achieve a complete remission with upfront conventional chemotherapy currently have several options for consolidative therapy including maintenance therapy with rituximab, autologous hematopoietic cell transplantation (HCT), and more recently, allogeneic HCT utilizing a reduced intensity conditioning (RIC) regimen.
  • In the autologous HCT setting, the added efficacy of rituximab is under active investigation as a method of in vivo purging during hematopoietic cell mobilization, as part of the conditioning regimen and as post-HCT maintenance therapy.
  • For patients with PTCL, autologous HCT is commonly offered at relapse but there are a few prospective series utilizing autologous HCT as consolidation of CR1 with encouraging results.
  • This review summarizes the current role of HCT for patients with MCL in first remission and for patients with PTCL as consolidation and for relapsed/refractory disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Mantle-Cell / surgery. Lymphoma, T-Cell, Peripheral / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8
  • (PMID = 18162229.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  • [General-notes] NLM/ Original DateCompleted: 20080104
  •  go-up   go-down


9. Saglam A, Hayran M, Uner AH: Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS; 2008 Sep;116(9):791-800
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas.
  • Multidrug resistance (MDR) is defined as resistance of tumor cells to a wide spectrum of structurally and functionally unrelated drugs.
  • One of the most important mechanisms in mediating MDR is that involving cellular drug efflux transporters.
  • Drug resistance is a common and formidable obstacle to therapy in mature T/NK-cell lymphomas and the MDR phenotype is thought to be one of the contributing mechanisms.
  • In this study we assessed the immunohistochemical expression of P-gp (P-glycoprotein), MRP-1 (multidrug resistance associated protein 1), BCRP (breast cancer resistance protein) and LRP (lung resistance protein) in 45 mature T/NK-cell lymphomas diagnosed at our hospital.
  • These findings show that our T/NK-cell lymphoma cases display high frequency of MDR protein expression.
  • [MeSH-major] ATP Binding Cassette Transporter, Sub-Family B / biosynthesis. ATP-Binding Cassette Transporters / biosynthesis. Lymphoma, Extranodal NK-T-Cell / metabolism. Multidrug Resistance-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Vault Ribonucleoprotein Particles / biosynthesis
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Aged, 80 and over. Child. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024599.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


10. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J: Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol; 2000 Jan;11(1):115-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
  • Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3.
  • Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma).
  • Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690400.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 80168379AG / Doxorubicin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García-Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E: High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol; 2003 Dec;14(12):1768-75
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
  • BACKGROUND: T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas.
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas.
  • However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined.
  • PATIENTS AND METHODS: From January 1990 to December 1999, 115 patients with PTCL underwent HDC/ASCT inside the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO) registry.
  • At diagnosis the median age was 41 years and 60% of patients presented with two or three risk factors from the adjusted International Prognostic Index (a-IPI).
  • Thirty-two per cent of patients were transplanted in first complete response (CR), 62% in chemosensitive disease and 5% in refractory disease.
  • RESULTS: Eighty-six per cent of the patients attained a CR and 5% a partial response (PR).
  • With a median follow-up of 37 months (range 1-133), overall survival (OS), time-to-treatment failure (TTF) and disease-free survival (DFS) at 5 years was 56%, 51% and 60%, respectively; for the 37 patients transplanted in first CR, OS and DFS at 5 years were 80% and 79%, respectively.
  • Lactase dehydrogenase (LDH), a-IPI and disease status pre-transplant were associated with outcome.
  • CONCLUSIONS: More than half of patients with chemosensitive disease who were transplanted are expected to be alive at 5 years.
  • Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630683.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


12. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A, Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB): Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol; 2008 May;19(5):958-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
  • AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).
  • PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.
  • RESULTS: Sixty-eight percent of patients received the planned treatment.
  • After chemotherapy, 20 patients reached complete response (CR), 4 partial response and 17 failed.
  • ASCT was carried out in 17 of 24 candidates due to lack of mobilization (three cases), toxicity (two), early relapse and patient decision (one each).
  • CR rate after treatment was 51%.
  • With a median follow-up of 3.2 years, 5 of 21 CR patients relapsed and 2 died in CR due to secondary neoplasms.
  • Twenty-two patients have died, with a 4-year overall survival of 39%.
  • International Prognostic Index was the main variable predicting survival.
  • No differences were seen among the 24 candidates according to whether or not they underwent ASCT.
  • CONCLUSION: This intensive regimen resulted in moderate CR rate, with manageable toxicity in PTCL.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2008 Aug;19(8):1512 [18662957.001]
  • (PMID = 18303032.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone
  •  go-up   go-down


13. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD: Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma; 2002 Sep;43(9):1769-75
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.
  • There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.
  • From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy).
  • Even though patients who presented with bulky disease or who achieved less than a complete response to chemotherapy were the ones typically treated with combined modality therapy rather than chemotherapy alone, there was no significant difference in local control (5-year rates: 60 vs. 70%, p = 0.49), progression-free survival (5-year rates: 65 vs. 60%, p = 0.62), or overall survival (5-year rates: 74 vs. 67%, p = 0.47) between the groups treated with combined modality therapy and chemotherapy alone.
  • Twelve relapses were limited to the initial site of disease; two involved the initial site and new sites, and one involved only new sites.
  • Based on the significant risk of relapse at the initial site of disease, different approaches, including chemotherapy with concomitant radiotherapy to doses > or = 45 Gy, warrant investigation.
  • [MeSH-major] Doxorubicin / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12685830.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


14. Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH: CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol; 2006 Jul;58(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
  • OBJECTIVE: The present study evaluated the feasibility of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy in patients with peripheral T cell lymphomas (PTCLs).
  • PATIENTS AND METHODS: Twenty-six patients with newly diagnosed PTCLs were enrolled into the pilot study.
  • Treatment consisted of classical CHOP plus etoposide 100 mg/m(2) intravenously (i.v.) on day 1 and gemcitabine 600 mg/m(2) i.v. on day 1 in a 3 week interval.
  • RESULTS: Fifteen complete responses (CR, 57.7%) or one unconfirmed complete response (uCR, 3.8%) and four partial responses (PR, 15.4%) were confirmed, giving an overall response rate of 76.9% (95% CI, 58.3-96.3%).
  • Median survival has not yet been reached, while median event free survival was 215 days at a median follow-up duration of 383 days.
  • The most severe haematological adverse event was neutropaenia, which occurred with a grade 4 intensity in 14 patients (53.8%).
  • However, there was no treatment-related death.
  • CONCLUSION: The CHOP-EG regimen was found to be feasible in patients with PTCLs.
  • For further investigation on the role of gemcitabine in the treatment of PTCLs, a more large scale phase II or phase III study is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Survival Rate. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308699.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Piekarz R, Frye R, Turner M, Wright J, Leonard J, Allen S, Bates S, for all collaborators: Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):3028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
  • : 3028 Background: Depsipeptide, FK228 (Fujisawa Pharmaceuticals), is the first of a new generation of histone deacetylase inhibitors to demonstrate consistent clinical activity in a specific tumor type.
  • As a result, we are currently conducting a multi-institutional phase II trial in patients with CTCL, PTCL, or other mature T cell lymphomas.
  • METHODS: This trial is accruing patients into 4 separate arms based on histology and prior therapy.
  • Depsipeptide is administered as a 4 hr infusion on days 1, 8, and 15 of a 28 d cycle.
  • In Arm 1, comprised of patients with CTCL who had not previously received more than 2 cytotoxic chemotherapy regimens, objective responses were observed in 7 of 14 patients, including 3 patients with complete response and 4 patients with partial response, for a response rate of 50%.
  • Of the 17 patients with PTCL enrolled, 4 (24%) achieved a PR lasting 9 and 12 months in 2 patients, and ongoing over 4 months in 2 patients.
  • Overall the drug is well tolerated, with observed toxicities including nausea, vomiting, fatigue, neutropenia, thrombocytopenia, and hypocalcemia.
  • Non-specific ST-T wave changes are noted by ECG, without changes in cardiac function.
  • Molecular endpoints have been studied in patient normal and malignant cells.
  • CONCLUSIONS: These results suggest that histone deacetylase inhibitors such as depsipeptide are active in patients with T cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015193.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • The long-term survival of conventional therapies has led the exploration of alternatives.
  • High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, has been explored in recent years with little experiences.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • The patients were stratified according to their International Prognostic Index (IPI), disease status at the time of transplant and histology type.
  • RESULTS: Twenty-nine subjects were identified, with a median age of 51; 13 patients had Anaplastic T cell, 18 patient had PTCL-nos, and 6 patients with angioimmunoblastic T cell lymphoma.
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.
  • A multivariate analysis and new risk stratification based on the IPI score system and disease status at time of transplant were employed.
  • However, such outcome was not statistically significant (p = 0.1360).
  • CONCLUSIONS: The status at time of transplant with new methods for evaluation of minimal residual disease may help in assessing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rao RA, Chin K, Pilichowska M, Foss F: Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging. J Clin Oncol; 2004 Jul 15;22(14_suppl):6706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging.
  • : 6706 Background: The T cell non-Hodgkin's lymphomas comprise a heterogeneous group of diseases which, with the exception of anaplastic large cell lymphoma, are associated with short response durations and survival after conventional cytotoxic chemotherapy .
  • Recently, a retrospective review by the Non-Hodgkin's Lymphoma Classification Project demonstrated that survival and failure-free survival were correlated with performance status and the International Prognostic Index (IPI).
  • METHODS: We performed a retrospective analysis of 35 patients (m=20, f=15) with non-cutaneous T-cell lymphoma treated at a single institution to determine whether clinical features or IPI classification were predictive of outcome.
  • The histopathologic subtypes included: AILD (5), NK-T cell lymphoma (2), PTCLu (14), HTLV-1 associated ATL (3), T-CLL (6), T-ALL (5).
  • The majority of patients had advanced disease (31 stage IV, 3 Stage III) at presentation.
  • Extranodal disease was found in 16 of 35, with bone marrow involvement in 8, visceral infiltration in 9, and skin in 6.
  • The majority of patients (68%) were treated with anthracycline based multi-agent chemotherapy.
  • High IPI score was associated with an overall higher incidence of relapse and a shorter median survival (21 months) compared to low IPI (114 months).
  • LDH and extranodal involvement were not predictive of outcome in this small cohort of patients.
  • Further multi-institutional studies are warranted to further explore the predictors of outcome in underrepresented histologic subtypes of T-cell NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Giaccone G, Rajan A, Carter C, Kelly R, Berman A, Spittler J, Espinoza-Delgado I, Lee M, Trepel J, Loehrer P: Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy is used for advanced disease.
  • There is no established role of second-line therapy in patients with refractory or recurrent disease.
  • Belinostat is an HDAC inhibitor with activity in cutaneous and peripheral T cell lymphoma and is being investigated in several solid tumors.
  • METHODS: Patients with recurrent thymoma or thymic carcinoma, progressing after platinum-based chemotherapy were eligible.
  • They were also required to have measurable disease, PS 0-2 and normal organ functions.
  • Belinostat was given iv at 1.0 g/m<sup>2</sup> on days 1-5 of a 21-day cycle until disease progression or intolerable side effects.
  • Treatment was well tolerated, with nausea being the most common side effect and well controlled with prophylactic antiemetics.
  • 21 patients are evaluable for response: 2 had a partial response (9+, 9+ m), 13 stable disease (3-11+ m) and 6 progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Dueck GS, Chua N, Prasad A, Stewart D, White D, vanderJagt R, Johnston JB, Belch A, Reiman T: Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol; 2009 May 20;27(15_suppl):8524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases.
  • : 8524 Background: Novel therapies are needed to improve outcomes in T-cell lymphomas.
  • We report the interim results of a prospective multicenter trial evaluating lenalidomide in T-cell lymphomas.
  • METHODS: Patients with relapsed and refractory T-cell lymphomas other than mycosis fungoides were prescribed oral lenalidomide (25mg daily) on days 1 to 21 of each 28 day cycle, with standardized dose reductions for toxicity.
  • Treatment continued until disease progression, death or unacceptable toxicity.
  • RESULTS: At the time of this interim analysis, 24 patients were enrolled in this study and 23 were evaluable for response.
  • The histology was peripheral T-cell unspecified (PTCL-u, n=10), angioimmunoblastic (n=7), anaplastic large cell (n=5), enteropathic T-cell (n=1) and hepatosplenic gamma/delta (n=1).
  • Median number of prior therapies was 1 (range, 0-4), and three had prior autologous stem cell transplant.
  • Four patients were previously untreated and not candidates for combination chemotherapy.
  • Median time from completion of prior therapy to the start of lenalidomide was 8 months (range, 1-48 months).
  • Two patients had stable disease (SD) for ≥3 cycles.
  • Responses were seen in anaplastic, angioimmunoblastic, and PTCL-u histologies.
  • Among the 9 patients with SD or better, median PFS was 168 days and median OS has not yet been reached with 241-696 days of follow-up.
  • The most common grade 3 adverse events were neutropenia (20.8%), febrile neutropenia (16.7%), and pain NOS (16.7%).
  • CONCLUSIONS: In relapsed and refractory T-cell lymphomas, oral lenalidomide monotherapy has clinical activity and toxicity is consistent with the known profile of lenalidomide.
  • Further study of lenalidomide in these diseases is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960899.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated peripheral T-cell lymphoma.
  • : e19551 Background: T-cell lymphomas (TCL) constitute 3% of all AIDS-related lymphomas.
  • These lymphomas comprise a diverse group of disease entities, including peripheral T-cell lymphomas (PTCL), which represent the most common subtype.
  • The aim of this study was to investigate the clinical and pathological features of HIV-associated PTCL.
  • METHODS: A MEDLINE search for cases of HIV-associated PTCL was conducted through December 2008.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.
  • Patients had a median age of 36 years with a male:female ratio of 4:1.
  • Seventeen patients (50%) had an opportunistic infection, but only 7 patients (26%) were on HAART treatment; 4 patients on HAART (57%) were alive at time of publication.
  • PTCL was extranodal in 75% of cases, affecting predominantly the oral cavity, lung, and GI tract.
  • Stage III and IV disease was found in 17 and 5 cases, respectively, accounting for 76% of the total cases.
  • T-cell receptor gene rearrangement was positive in 10 out of 10 (100%) analyzed cases.
  • Therapy for PTCL was administered in 23 cases (68%), while 10 cases (30%) did not receive therapy; 9 of the treated patients (39%) received CHOP with a 33% remission rate.
  • Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.
  • CONCLUSIONS: HIV-associated PTCL tends to affect young male individuals with low CD4 counts.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated PTCL appears to be related to advanced stage at presentation, presence of B symptoms, elevated LDH levels, prominent extranodal disease, and poor response to CHOP chemotherapy.
  • The role of HAART and EBV in the development of PTCL needs further clarification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Oki M, Isozaki M, Nakamura N, Kikuchi A, Tsuchiya T, Arbogast P, Ogawa Y, Ando K: A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL). J Clin Oncol; 2009 May 20;27(15_suppl):e19521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis for the survival of nodal peripheral T-cell lymphoma (PTCL).
  • : e19521 Background: Nodal peripheral T-cell lymphoma (PTCL) is uncommon lymphoma with various subtypes and poor prognosis.
  • There is no definitive therapeutic improvement by conventional chemotherapy (CT) for decades.
  • However, the superiority of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has remained inconclusive.
  • The infrequency of PTCL is an obstacle to perform a large prospective study.
  • We conducted a retrospective study of fifty six patients with three major nodal PTCL, histologically classified as PTCL-not specified (NOS, n=29), angioimmunoblastic T-cell lymphoma (AITL, n=19), and ALK-negative anaplastic large cell lymphoma (ALCL, n=8) who underwent ASCT (n=14) or not (n=42) after CT in Tokai University Hospital, Ebina General Hospital, and Hadano Red Cross Hospital, Kanagawa, Japan between 1997 and 2008.
  • We determined whether international prognostic index (IPI), serum soluble IL-2 receptor level (sIL-2R) and ASCT were correlated with the survival.
  • METHODS: Retrospective, multicenter cohort study by time-dependent or non-time-dependent multivariate survival analysis with Cox proportional hazard regression.
  • In non-time-dependent analysis, both ASCT and sIL-R were significant prognostic factors for overall survival (OS).
  • But in time-dependent manner, the significant effect of ASCT was offset for OS.
  • On the other hand, ASCT was only important effect on progression-free survival (PFS) by non-time-dependent analysis, which HR was 0.20 (95%CI: 0.07-0.55, p=0.02).
  • After time-dependent analysis, no variates influenced PFS.
  • CONCLUSIONS: The OS advantage of high-dose chemotherapy followed by ASCT is offset by time-dependent Cox proportional hazard analysis.
  • Prospective multicenter randomized trial will be needed to show or not to show an advantage for ASCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Schmitz N, Ziepert M, Nickelsen M, Wolf SP, Truemper L, Loeffler M, Ho A, Metzner B, Rosenwald A, Pfreundschuh M: Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL). J Clin Oncol; 2009 May 20;27(15_suppl):8564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL).
  • : 8564 Background: T-cell lymphomas represent a heterogeneous group of malignancies difficult to diagnose and to treat.
  • Chemotherapy regimens (CHOP-14 and CHOEP) had significantly improved outcomes of patients with aggressive B-NHL.
  • METHODS: Between 1993 and 2006 we treated 329 pts with ALK-positive ALCL (73 pts), ALK-negative ALCL (108 pts), PTCL, NOS (68 pts), AITL (28 pts), NK-/T-cell lymphoma (18 pts), and rare T-cell lymphomas on prospective studies.
  • All pts received CHOP ± etoposide (E) every 2 or 3 weeks; in pts <=60 yrs C, H, and E were escalated to further improve outcomes.
  • The IPI discriminated between pts with a favorable (IPI 0, 1: OS 73%), moderate (IPI 2: OS 55%), and poor prognosis (IPI 3: OS 35%; IPI 4, 5: OS 19%) at 3 yrs.
  • OS, EFS were significantly better for ALK-positive ALCL but did not significantly differ for pts in other histological subgroups.
  • Neither shortening of the treatment interval (CHOP-14) nor the addition of E (CHOEP-21 or -14) significantly improved outcome of elderly pts.
  • In younger pts (ALK-positive ALCL were excluded) and good-risk disease (LDH <= N) there was a trend for better EFS after the addition of E to CHOP (EFS 63% vs. 48%, p = 0.065).
  • The MegaCHOEP protocol (Schmitz et al., CANCER 2006) failed to improve treatment results for younger pts with poor-risk disease (EFS at 3 yrs: 25.9%, 95% CI: 10.4-41.4); the prospective study comparing MegaCHOEP with CHOEP-14 was stopped for pts with T-cell lymphoma.
  • All other pts did poorly; CHOP-14 or the addition of E failed to significantly improve outcomes.
  • Notably, also the MegaCHOEP protocol characterized by repetitive high-dose therapy and ASCT did not result in significant improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH: Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. J Clin Oncol; 2009 May 20;27(15_suppl):8501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study.
  • METHODS: Phase II trial is being conducted in patients diagnosed with advanced lymphomas who had ≥ 1 prior therapy.
  • RESULTS: The phase II study has accrued 28 lymphoma patients (21 non-Hodgkin's, 7 Hodgkin's); median age at baseline 61 years, ECOG ≤2, median number of prior therapies 3.
  • Of these, 1 subject (PTCL) has achieved a complete response, 3 - partial responses (2 marginal zone, 1 Hodgkin's), and 4 stable disease (2 PTCL, 1 DLBCL, 1 Hodgkin's).
  • A total of 63 cycles of darinaparsin have been administered to subjects with lymphoma. No Gr.
  • 3 or higher drug-related AEs were reported.
  • Two SAEs were considered possibly drug-related (fall; neutropenic fever).
  • Phase I studies accrued 35 patients; median age at baseline 58 years, ECOG ≤2, median number of prior therapies 3.
  • Predominant tumor types include: colorectal (17), pancreatic (3), NHL (3).
  • Drug-related AEs include nausea/vomiting, fatigue, decreased appetite/anorexia.
  • CONCLUSIONS: Darinaparsin is active in heavily pretreated patients with advanced lymphoma and has been very well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C: High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol; 2007 Jun;86(6):435-42
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
  • Although the role of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in the treatment of aggressive lymphoma has been established in several large prospective studies, its effectiveness in patients with peripheral T cell lymphoma (PTCL) has not been defined.
  • We aimed to evaluate the efficacy of HDT and ASCT and prognostic factors for survival in patients with PTCL.
  • We retrospectively analyzed the results of 40 PTCL patients treated with HDT and ASCT at Asan Medical Center between January 1995 and December 2005.
  • Twenty patients had PTCL-U (peripheral T cell lymphoma, unspecified), 10 had extranodal natural killer/T cell lymphoma, 5 had anaplastic large cell lymphoma, 3 had angioimmunoblastic T cell lymphoma, 1 had hepatosplenic gammasigma T cell lymphoma, and 1 had disseminated mycosis fungoides.
  • Disease status at transplant was complete response (CR)1 in 3 patients, CR2 or greater in 8, partial remission in 25, and refractory in 4.
  • Ten patients (25%) remain alive without evidence of disease.
  • The median OS of 11 patients with CR at ASCT was not reached; of these, 7 patients (63.6%) were alive with CR.
  • Chemosensitive patients with PTCL who achieved CR before ASCT seem to benefit from HDT and ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft Survival. Hematopoietic Stem Cell Mobilization / methods. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256144.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Hauenstein E, Seidl S, Schneider KT, Fischer T: Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age. Onkologie; 2010;33(12):692-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age.
  • Especially in lymphomas, incidence and long-time survival have increased.
  • Hematologists and gynecologists have to treat more and more female patients who wish to become pregnant despite their disease and/or after finishing treatment.
  • CASE REPORT: We report on a 28-year-old patient with highly malignant non-Hodgkin's lymphoma (peripheral T cell lymphoma, Ann Arbor stage IV) and main manifestation at the gastric antrum, with a distinct wish for becoming pregnant.
  • Chemotherapy was strongly recommended to her, but she refused.
  • After she had conceived, the disease recurred, followed by stillbirth in week 19 of gestation and death due to gastric perforation and septic shock.
  • CONCLUSIONS: Facing the risk of sterility after chemotherapy should not induce patients to refuse chemotherapy and risk their lives.
  • Treatment of young female cancer patients should therefore always include a thorough discussion about other ways of preserving fertility for the time after treatment.
  • Such strategies exist, although their success is still limited and not every patient is eligible for them.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Infertility, Female / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / surgery. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / surgery. Stillbirth. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Refusal
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Fatal Outcome. Female. Gastrectomy. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / toxicity. Pregnancy. Pregnancy Trimester, Second. Pyloric Antrum / pathology. Rupture, Spontaneous. Shock, Septic / pathology. Stomach Rupture / parasitology. Vincristine / administration & dosage. Vincristine / toxicity


26. Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol; 2007 Jun;60(1):129-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
  • PURPOSE: The present study was conducted to evaluate the safety and efficacy of alemtuzumab plus CHOP chemotherapy for patients with peripheral T-cell lymphomas (PTCLs).
  • PATIENTS AND METHODS: Twenty patients with newly diagnosed PTCLs were enrolled.
  • The treatment consisted of classical CHOP plus alemtuzumab (10 mg i.v. on day 1 and 20 mg i.v. on day 2 in the first cycle, then 30 mg i.v. on day 1 in the subsequent cycles) based on 3-week intervals.
  • The most severe hematologic adverse event was neutropenia, which occurred with a grade-4 intensity in 18 patients (90.0%).
  • Five patients (25%) experienced cytomegalovirus (CMV) reactivation, while three patients developed CMV diseases, such as pneumonitis or retinitis.
  • There were two treatment-related deaths.
  • CONCLUSION: The alemtuzumab plus CHOP chemotherapy seemed to produce active antitumor activity in terms of the complete response rates in patients with PTCLs.
  • However, since high infectious and hematologic toxicities were observed, careful monitoring and early treatment are needed to prevent treatment-related mortality.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Immunoglobulin G / analysis. Immunoglobulin G / immunology. Leukopenia / chemically induced. Lymphopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Pilot Projects. Prednisone / adverse effects. Prednisone / therapeutic use. Prognosis. Severity of Illness Index. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use. Vomiting / chemically induced

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17406867.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
  • Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy.
  • Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).
  • RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure.
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


28. Foss FM: Enhancing existing approaches to peripheral T-cell lymphoma. Semin Hematol; 2010 Apr;47 Suppl 1:S8-10
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing existing approaches to peripheral T-cell lymphoma.
  • The National Comprehensive Cancer Network (NCCN) practice guidelines for peripheral T-cell lymphoma (PTCL) accentuate the lack of standard treatment options for this disease.
  • Outcomes with conventional therapies, many of which are borrowed from B-cell lymphoma, are poor.
  • Strategies to enhance existing approaches include creating a new platform for first-line therapy and adding novel agents, such as denileukin diftitox, to existing chemotherapy platforms.
  • Furthermore, to improve outcomes, patients must reach transplant through effective first-line therapies.
  • Additionally, treatment should be individualized based on histopathologic subtype, as all PTCL patients will not respond to the same treatment regimen.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Therapies, Investigational
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. T-Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Inc.
  • (PMID = 20359584.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


29. Hassan AS, Elner VM: Orbital peripheral T-cell lymphoma in a child. Ophthal Plast Reconstr Surg; 2005 Sep;21(5):385-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital peripheral T-cell lymphoma in a child.
  • A 6-year-old boy with known peripheral T-cell lymphoma had progressive left periorbital swelling and CT findings consistent with abscess or necrosis.
  • Biopsy revealed peripheral T-cell lymphoma and associated necrosis involving the lacrimal gland and surrounding orbital tissue.
  • Immunohistochemical and T-cell receptor gene rearrangement studies confirmed the diagnosis.
  • The patient responded to local radiation and systemic chemotherapy.
  • This is the first pathologically confirmed case of orbital peripheral T-cell lymphoma with subpanniculitic features.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Child. Combined Modality Therapy. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Male. Receptors, Antigen, T-Cell, gamma-delta / genetics. Tomography, X-Ray Computed. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234707.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


30. Chen X, Dong DF, Wu YY, Huang HY, Liang J, Li EX: [Clinical characteristics and survival of peripheral T-cell lymphoma-not otherwise specified: a report of 57 cases]. Zhonghua Zhong Liu Za Zhi; 2009 Dec;31(12):916-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and survival of peripheral T-cell lymphoma-not otherwise specified: a report of 57 cases].
  • OBJECTIVE: To analyze the clinical characteristics and survival data of 57 patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
  • METHODS: The medical records of 57 patients with PTCL-NOS classified according to the revised REAL-WHO criteria, treated from Jan 1993 to Dec 2007 at the First and the Third affiliated Hospitals of Medical School of Xi'an Jiaotong University, were retrospectively evaluated by K-M univariate and COX multivariate analysis.
  • Nine of the 57 patients (15.8%) were treated with chemo-radiotherapy, 43 (75.4%) with chemotherapy, 3 (5.3%) with radiotherapy, and 2 with supported treatment alone (2.5%).
  • The overall response rate was 87.3%, with a complete remission (CR) rate of 60.0% in 55 evaluable cases.
  • The 1-, 3-, and 5-year overall survival (OS) rates were 67.0%, 48.0% and 24.3%, respectively, with a median follow-up of 30.4 months (ranged 1-100 months).
  • The median survival time (MST) was 36.0 months.
  • Multivariate analysis showed that the prognostic index for T cell lymphoma (PIT) score was an independent prognostic factor for PTCL-NOS (P < 0.05), but bone marrow involvement, performance status, extranodal involvement, stage, B symptom were not independent prognostic factors.
  • CONCLUSION: Although conventional chemotherapy yields a high response rate for PTCL-NOS, the long-term survival is still low and further investigation for optional treatment is needed.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193331.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The radiation dose was 39.9-40.5 Gy in 30 fractions.
  • The median treatment time was 22 days with twice-daily involved-field RT.
  • Local control was defined as maintenance of local complete response, complete response-unconfirmed, or lack of local progression with a partial response.
  • Recurrence or progression outside the RT volume was regarded as distant disease.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The disease bulk was > or =10 cm in 35% (n = 12).
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Tsuchiyama J, Imajo K, Yoshino T, Nanba N, Toyota A, Yoshida C, Fujii K, Kondo E, Okazuka K, Hashimoto S, Toba K, Fuse I, Aizawa Y, Harada M, Tsubota T: High-dose chemotherapy and autologous peripheral blood stem cell transplantation for treatment of unspecified peripheral T-cell lymphoma presented with hepatosplenomegaly and hypercytokinemia syndrome: report of three cases. Ann Hematol; 2002 Oct;81(10):588-92
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous peripheral blood stem cell transplantation for treatment of unspecified peripheral T-cell lymphoma presented with hepatosplenomegaly and hypercytokinemia syndrome: report of three cases.
  • We report here three cases of peripheral T-cell lymphoma unspecified (PTCL-US), which presented with bone marrow infiltration and hepatosplenomegaly and were successfully treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • All three patients were negative for anti-adult T-cell leukemia antibody.
  • The International Prognostic Index was high for all three patients, and they all achieved complete remission after the intensive chemotherapy for remission induction.
  • One patient died due to cerebrovascular disease without relapse 18 months after auto-PBSCT.
  • The other two patients are still alive and have not suffered from relapse.
  • Our observations suggest that auto-PBSCT following HDCT may be an effective and safe therapeutic modality for high-risk PTCL-US patients characterized by hepatosplenomegaly and cytokine-induced syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Aged. Cytokines / blood. Female. Gene Rearrangement. Genes, T-Cell Receptor beta. Hepatomegaly / therapy. Humans. Male. Middle Aged. Splenomegaly / therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424541.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


33. Prochazka V, Faber E, Raida L, Vondrakova J, Kucerova L, Jarosova M, Indrak K, Papajik T: Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar;153(1):63-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
  • BACKGROUND: Nodal peripheral T-cell lymphomas (PTCLs) are infrequent subtypes of non-Hodgkin's lymphomas.
  • The WHO classification recognizes three subgroups of nodal PTCL: peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), anaplastic large cell lymphoma (ALCL) and angioimmunoblastic lymphoma (AIL).
  • The clinical course is aggressive and despite multiagent chemotherapy, the median survival is about 2 years.
  • Optimal first-line chemotherapy is not established and the role of high-dose therapy with autologous stem cell support is still controversial.
  • AIM: To analyze the long-term outcome of PTCL patients treated with intensive first-line chemotherapy with highdose therapy and autologous transplant consolidation.
  • METHOD: Sequential chemotherapy protocol consisting of 3 cycles of CHOEP-21-like regimen (PACEBO), 1 cycle of an ifosfamide and methotrexate-based regimen (IVAM) and a priming regimen with high-dose cytosine arabinoside (HAM).
  • Consolidation was provided with myeloablative conditioning (BEAM 200) and autologous stem cell support.
  • Eighty-four patients with aggressive high-risk lymphoma were treated with the sequential protocol from 2000 to 2007 in our institution.
  • Here we report our experience with 18 patients with nodal PTCL (10 PTCL, NOS; 3 ALCL, ALKnegative; 2 ALCL, ALK-positive; 2 ALCL, unknown ALK status; 1 AIL).
  • RESULTS: Eleven (61 %) patients achieved complete remission, 3 (17 %) partial remission and 4 (22 %) patients failed the procedure.
  • After a median follow-up of 25.7 months, nine patients relapsed or progressed (6 PTCL, NOS; 2 ALCL ALK-positive; 1 ALCL ALK-negative; median 14.1 months) and four patients died (lymphoma progression).
  • CONCLUSION: Our results show that intensive first-line chemotherapy with high-dose therapy and autologous transplant consolidation offers a chance for long-term survival in patients with chemosensitive PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / mortality. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365529.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


34. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia; 2006 Sep;20(9):1533-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
  • We report the results of two prospective phase II studies investigating the role of high-dose sequential chemotherapy, followed by autologous stem cell transplantation (ASCT) in 62 patients with advanced stage peripheral T-cell lymphomas (PTCLs) at diagnosis.
  • Conditioning regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) or carmustine, etoposide, Ara-C and melphalan followed by peripheral blood stem cell autografting.
  • In an intent-to-treat analysis, 46 out of 62 patients (74%) completed the whole programme, whereas 16 patients did not undergo ASCT, mainly because of disease progression.
  • At a median follow-up of 76 months, the estimated 12-year overall (OS), disease-free and event-free survival (EFS) were 34, 55 and 30%, respectively.
  • OS and EFS were significantly better in patients with anaplastic lymphoma-kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), as compared with the remaining PTCL.
  • Overall treatment-related mortality rate was 4.8%.
  • In conclusion, our findings indicate (1) up-front high-dose therapy and ASCT are feasible, but could induce a high rate of long-term CR only in patients with ALK-positive ALCL and (2) the achievement of CR before autografting is a strong predictor of better survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Follow-Up Studies. Humans. Middle Aged. Prognosis. Prospective Studies. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871285.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


35. Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW: Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant; 2009 Jan;15(1):118-25
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
  • High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T cell lymphoma patients with poor prognosis.
  • However, the effectiveness of HDT/ASCT in patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that predict better outcomes, have not been identified.
  • We retrospectively investigated the clinical outcomes and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified (PTCL-U) between March 1995 and February 2007.
  • According to the age-adjusted International Prognostic Index (a-IPI) and the prognostic index of PTCL (PIT), 8 patients (12.5%) were in the high-risk group and 16 (26.6%) had the 2-3 PIT factors, respectively.
  • Failure to achieve CR at transplantation and high PIT are negative predictable factors for survival following HDT/ASCT in patients with PTCL-U.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135950.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • Three of the 4 patients with unspecified PTCL (PTCLu) achieved complete response (CR); 1 patient relapsed and 1 died of secondary leukemia after consolidation therapy.
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage


37. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R, Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol; 2003 Dec 1;21(23):4402-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
  • PURPOSE: Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin's lymphomas (NHLs).
  • Usual prophylaxis and treatment of hyperuricemia consist of hydration, alkalinization, and administration of allopurinol.
  • This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy.
  • PATIENTS AND METHODS: A total of 100 patients from Groupe d'Etude des Lymphomes de l'Adulte centers, with diffuse large B-cell lymphoma (n = 79); anaplastic large-cell lymphoma (n = 6); peripheral T-cell lymphoma (n = 8); transformation of indolent lymphoma (n = 5); Burkitt's lymphoma (n = 1); and lymphoblastic lymphoma (n = 1) were enrolled from May 2001 to June 2002.
  • Before chemotherapy, 66% of patients had elevated lactate dehydrogenase (LDH), including 28% with LDH above 1,000 U/mL.
  • Rasburicase 0.20 mg/kg/d intravenously for 3 to 7 days was started the day before or at day 1 of chemotherapy.
  • UA levels were measured 4 hours after rasburicase injection, then daily during treatment.
  • RESULTS: All patients responded to rasburicase, as defined by normalization of UA levels maintained during chemotherapy.
  • The control of UA was obtained within 4 hours after the first injection of the drug.
  • No patient exhibited increased creatinine levels or required dialysis during chemotherapy.
  • CONCLUSION: Rasburicase is the treatment of choice to control UA and prevent tumor lysis syndrome in adult patients with aggressive NHL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hyperuricemia / drug therapy. Hyperuricemia / prevention & control. Lymphoma, Non-Hodgkin / drug therapy. Urate Oxidase / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Creatinine / blood. Female. Humans. Injections, Intravenous. Male. Middle Aged. Recombinant Proteins / therapeutic use. Remission Induction. Safety. Treatment Outcome. Tumor Lysis Syndrome / drug therapy. Tumor Lysis Syndrome / etiology. Uric Acid / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Aug 15;22(16):3430-1; author reply 3431-2 [15310789.001]
  • (PMID = 14581437.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 268B43MJ25 / Uric Acid; AYI8EX34EU / Creatinine; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


38. Gaffan J, Herbertson R, Davis P, Dogan A, Jones A: Bilateral peripheral T-cell lymphoma of the fallopian tubes. Gynecol Oncol; 2004 Dec;95(3):736-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral peripheral T-cell lymphoma of the fallopian tubes.
  • BACKGROUND: Lymphoma of the female genital tract is rare, and usually involves the ovaries or the uterus.
  • Most cases of fallopian tube lymphoma reflect disease arising in the ovaries.
  • All previously reported cases of primary lymphoma of the fallopian tube were of B cell lineage.
  • CASE: A 51-year-old woman presented with systemic upset and a pelvic mass.
  • At laparotomy, both fallopian tubes were inflamed and histological examination revealed peripheral T-cell lymphoma.
  • At staging, she had IIB(E) disease, and she was treated with six cycles of CHOP-M chemotherapy.
  • CONCLUSION: Our case is unusual in that this is the first described case of peripheral T-cell lymphoma arising in the fallopian tubes and is moreover unusual because of the involvement of both fallopian tubes without involvement of other gynaecological organs.
  • The clinical course was favourable with complete remission maintained for more than 5 years.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581994.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood; 2004 Apr 15;103(8):2920-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
  • Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy.
  • We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL.
  • All had clinical stage III or IV disease.
  • Patients received a rapidly escalating dosage of alemtuzumab during the first week and, thereafter, 30 mg intravenously 3 times per week for a maximum of 12 weeks.
  • Five patients died of causes related to the treatment, in combination with advanced disease.
  • Further studies are warranted in younger patients and patients with less advanced disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bone Marrow / drug effects. Drug Resistance, Neoplasm. Female. Humans. Infection / etiology. Male. Middle Aged. Pilot Projects. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15070664.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


40. Yu YX, Shi YK, He XH, Zhou LQ, Zhou SY, Dong M, Feng FY, Sun Y: [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases]. Zhonghua Yi Xue Za Zhi; 2007 Oct 16;87(38):2714-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
  • OBJECTIVE: To summarize the clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified (PTCL-US).
  • METHODS: The medical records of 78 patients with PTCL-US classified according to the revised European and American lymphoma (REAL) or WHO criteria, 58 males and 20 females, aged 39 (9 - 75), 46 of them (59%) being at the stages III/VI and 40 cases (51.2%) with extranodal involvement), treated from Jan 1994 to Dec 2004 in the Cancer Hospital/Institute, Chinese Academy of Medical Sciences, were retrospectively analyzed.
  • 34 cases (43. 7%) were treated with chemoradiotherapy, and 43 (55%) with chemotherapy alone.
  • After the first line treatment the complete recovery (CR) rate and partial recovery (PR) rate were 55.1% (43/78) and 25.6% (20/78) respectively.
  • 15 cases (19.2%) showed progressive disease (PD) or stable disease (SD).
  • Achieving CR or PR after first-line treatment, 13 cases received autologous peripheral blood stem cell transplantation (APBSCT).
  • The 5-year OS of the CR, PR, and PD/SD groups were 65.1%, 21.9%, and 0% respectively.
  • The 5-year OS for the patients treated with first-line APBSCT was 61.5%, not significantly different from that of the patients treated with conventional dose therapy alone (52.3%, P = 0.894).
  • Univariate analysis showed that the factors associated with a worse OS included stage III/IV (P = 0.001), high LDH (P = 0.0001), behavior state score >or= 2 (P = 0.001), and bone marrow involvement (P = 0.011).
  • International prognostic index and prognostic index for peripheral T-cell lymphoma both predicted the overall survival.
  • CONCLUSION: A rare lymphoma with aggressive presentation, PTCL-US responds poorly to conventional treatment.
  • APBSCT is safe and feasible when CR or PR is achieved after first line treatment.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167252.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


41. Avilés A, Castañeda C, Neri N, Cleto S, Talavera A, González M, Huerta-Guzmán J, Nambo MJ: Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Med Oncol; 2008;25(3):360-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified.
  • We performed a controlled clinical trial to define the use of a brief therapy: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone) compared with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of peripheral T-cell lymphoma unspecific (PTCLu).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1385-9 [15359637.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1426-31 [1712837.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1601-8 [15378507.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] Med Oncol. 2003;20(1):13-7 [12665679.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1425-31 [11720423.001]
  • (PMID = 18247163.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; CMED protocol
  •  go-up   go-down


42. Hagner N, Joerger M: Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res; 2010;2:293-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer chemotherapy: targeting folic acid synthesis.
  • Methotrexate is one of the earliest anticancer drugs and is extensively used in lymphoma, acute lymphoblastic leukemia, and osteosarcoma, among others.
  • Pemetrexed has been approved in combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer, as a single agent for relapsed non-small-cell lung cancer after platinum-containing chemotherapy, and in combination with cisplatin for the treatment of pleural mesothelioma.
  • Pralatrexate has recently been approved in the United States for relapsed or refractory peripheral T-cell lymphoma.
  • This article gives an overview of the cellular mechanism, pharmacology, and clinical use of classical and newer antifolates and discusses some of the main resistance mechanisms to antifolate drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1948 Jun 3;238(23):787-93 [18860765.001]
  • [Cites] Expert Rev Mol Med. 2009;11:e4 [19173758.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2038-45 [19307503.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] Am J Health Syst Pharm. 2009 Nov 1;66(21):1890 [19850775.001]
  • [Cites] Oncology (Williston Park). 2009 Nov 30;23(13):1133-40 [20043461.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):673-7 [20125159.001]
  • [Cites] Clin Cancer Res. 2010 May 15;16(10):2872-80 [20460481.001]
  • [Cites] J Clin Oncol. 2010 Sep 20;28(27):e482-3; author reply e484 [20606096.001]
  • [Cites] Anticancer Drugs. 2010 Sep;21(8):777-84 [20634689.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):2-7 [6583327.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(1):18-25 [6690069.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1649-55 [7602354.001]
  • [Cites] Biochemistry. 1994 Feb 8;33(5):1209-15 [8110752.001]
  • [Cites] Biochemistry. 1997 Apr 15;36(15):4399-411 [9109647.001]
  • [Cites] Cancer Invest. 1993;11(1):36-45 [8422595.001]
  • [Cites] Leukemia. 1996 Mar;10(3):439-46 [8642859.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):353-8 [14735176.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):13-7 [15655931.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4425-30 [15899835.001]
  • [Cites] Cell. 2005 Sep 9;122(5):789-801 [16143108.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8414-22 [16166320.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34 [16612649.001]
  • [Cites] Oncologist. 2006 Jun;11(6):694-703 [16794248.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):283-7 [16809156.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):71-80 [16842380.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):85-94 [16957834.001]
  • [Cites] Cell. 2006 Dec 1;127(5):917-28 [17129779.001]
  • [Cites] Cell Metab. 2007 Jan;5(1):5-6 [17189201.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):111-28 [17334909.001]
  • [Cites] Science. 1947 Dec 19;106(2764):619-21 [17831847.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):599-604 [18504579.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2046-51 [18528741.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30189-98 [9804775.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):427-32 [10501918.001]
  • [Cites] Pharmacol Ther. 2000 Mar;85(3):191-205 [10739874.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):30855-63 [10899164.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(6):477-87 [11138461.001]
  • [Cites] Clin Pharmacokinet. 2000 Dec;39(6):429-43 [11192475.001]
  • [Cites] Oncology. 2001;60(2):134-40 [11244328.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):478-86 [11872339.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Biochem Pharmacol. 2002 Aug 15;64(4):669-75 [12167486.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3832-4 [12411325.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8935-41 [12519783.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Aug;15(5):227-32 [12924450.001]
  • [Cites] Proc Soc Exp Biol Med. 1958 Feb;97(2):429-31 [13518295.001]
  • [Cites] N Engl J Med. 1958 Jul 10;259(2):66-74 [13566422.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1434-8 [1371715.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6):707-19 [1462168.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2071-6 [15341981.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):521-4 [1732038.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2424-31 [19671745.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1323-9 [2414316.001]
  • [Cites] J Biol Chem. 1987 Oct 5;262(28):13520-6 [2443493.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):745-8 [301783.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5573-9 [3416310.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;15(2):101-4 [3874719.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):978-82 [3971388.001]
  • [Cites] Biochem Biophys Res Commun. 1973 May 1;52(1):27-34 [4197190.001]
  • [Cites] Ann N Y Acad Sci. 1971 Nov 30;186:400-22 [5289428.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):5007-17 [5303004.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3190-5 [6204743.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):8-15 [6699660.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):758-65 [7476904.001]
  • [Cites] Biochem Pharmacol. 1994 Feb 11;47(4):659-65 [7510479.001]
  • [Cites] Biochem Pharmacol. 1994 Mar 15;47(6):1019-27 [7511899.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22974-9 [7559435.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):459-71 [7565626.001]
  • [Cites] Biochemistry. 1995 Apr 25;34(16):5660-5 [7727426.001]
  • [Cites] Blood. 1995 Jan 15;85(2):500-9 [7812005.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):566-73 [7834626.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):901-6 [7877646.001]
  • [Cites] Clin Pharmacokinet. 1994 Mar;26(3):190-200 [8194282.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1154-9 [8320744.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Biochem J. 1997 Nov 1;327 ( Pt 3):759-64 [9581553.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):176-81 [9754649.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):348-57 [10023702.001]
  • [Cites] Curr Med Chem. 1999 Apr;6(4):329-52 [10101216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):775-82 [10498396.001]
  • [Cites] Lancet. 1999 Nov 20;354(9192):1824-5 [10577674.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):24-32 [10598551.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):33-7 [10598552.001]
  • [Cites] Mol Genet Metab. 2000 Aug;70(4):310-5 [10993718.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3705-12 [10999764.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1923-31 [11919253.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):629-40 [12144527.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):3-17 [12571805.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):24-9 [12571807.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7537-52 [14576857.001]
  • (PMID = 21301589.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3033035
  • [Keywords] NOTNLM ; antifolates / cancer / folate metabolism / methotrexate / molecular pharmacology / pemetrexed
  •  go-up   go-down


43. Chihara T, Wada N, Kohara M, Matsui T, Masaya H, Maeda T, Shibayama H, Kanakura Y, Tani M, Morii E, Aozasa K: Peripheral T-cell lymphoma of Lennert type complicated by monoclonal proliferation of large B-cells. Pathol Res Pract; 2010 Mar 15;206(3):185-90
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma of Lennert type complicated by monoclonal proliferation of large B-cells.
  • A biopsy was made (LN1) and diagnosed as peripheral T-cell lymphoma.
  • The lesion remitted completely over a period of about 51 months after combination chemotherapy, but erythematous papules, systemic lymphadenopathy, and fever of 38 degrees appeared.
  • LN1 displayed the typical histologic and immunohistochemical features of Lennert lymphoma, i.e., diffuse proliferation of small to large lymphoid cells of CD3+, CD4+, CD8- immunophenotype accompanied by numerous clusters of epithelioid histiocytes.
  • Clonality analysis revealed the persistent presence of an identical T-cell clone in LN1 and LN2.
  • Clonal bands of immunoglobulin heavy (IgH) chain gene were detected in LN2 but not in LN1.
  • Clonality analysis revealed the presence of a T-cell clone identical to LN1 and LN2 with no B-cell clone, indicating the recurrence of PTCL.
  • Taken together, EBV-positive large B-cell lymphoma appeared transiently in the course of "Lennert lymphoma".
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Herpesvirus 4, Human. Humans. Immunophenotyping. In Situ Hybridization. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19481878.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


44. Peng YL, Huang HQ, Lin XB, Xia ZJ, Li YH, Wang W, He YJ, Pan ZH, Jiang WQ, Guan ZZ: [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]. Ai Zheng; 2004 Aug;23(8):943-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
  • BACKGROUND & OBJECTIVES: The biological behavior of peripheral T-cell lymphoma (PTCL) are different from that of B-cell non-Hodgkin's lymphoma (NHL).
  • It shows low chemosensitivity, high incidence of relapse, poor prognosis, and has no standard chemotherapy regimen.
  • The efficacy of CHOP is poor for PTCL.
  • This study was to evaluate the efficacy and toxicity of EPOCH regimen for PTCL.
  • METHODS: EPOCH regimen(doxorubicin/epirubicin, vincristine, etoposide over 96 hours' infusion with bolus cyclophosphamide,and oral prednisone) was administered to 21 patients with PTCL.
  • According to WHO classification criteria, 21 cases of PTCL concluded 7 peripheral T-cell lymphoma unspecified (PTCL-U), 7 NK/T-cell lymphoma (NK/TCL), 5 anaplastic large cell lymphoma (ALCL), 1 Mycosis fungoides/Sezary syndrome (MF/SS), and 1 subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
  • RESULTS: Of 21 patients, 20 were eligible to evaluate treatment efficacy.
  • The RRs of patients with NK/TCL, PTCL-U, and ALCL were 71.4% (5/7), 100.0% (6/6), and 80.0%(4/5); the CR rates were 57.1% (4/7), 50.0% (3/6), and 40.0% (2/5).
  • Seventy cycles of chemotherapy were administered to 21 patients.
  • Other toxicities were mild, no treatment-related mortality occurred.
  • CONCLUSION: EPOCH was effective and well tolerant for the patients with PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15301720.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


45. Hashino S, Hirota G, Hasegawa M, Chiba K, Toyoshima N, Suzuki S, Kurosawa M, Musashi M, Asaka M: Peripheral T-cell lymphoma in a patient with osteopetrosis. Ann Hematol; 2001 Jun;80(6):376-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma in a patient with osteopetrosis.
  • Osteopetrosis is a rare genetic disorder in which the function of osteoclasts is defective, resulting in impaired bone resorption.
  • This disease is usually accompanied by myelosuppression due to decreased marrow space and by osteomyelitis, especially in the submandibular bone.
  • We report the case of a 72-year-old woman with an autosomal dominant form of osteopetrosis who suffered from peripheral T-cell lymphoma.
  • Accurate clinical and pathological diagnoses and staging were difficult due to nonspecific reactive hyperplasia of the lymph nodes, even though we used several scintigraphic techniques and [18F]fluorodeoxyglucose positron emission tomography.
  • We also paid special attention to myelosuppression and exacerbation of osteomyelitis after combination chemotherapy.
  • The patient achieved complete remission after four courses of chemotherapy and this status has been maintained for 6 months.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / etiology. Osteopetrosis / complications
  • [MeSH-minor] Aged. Female. Genes, Dominant. Humans. Japan. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11475155.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Shi YL, Yin HL, Zhou XJ, Zhou HB, Lu ZF: [Primary peripheral T-cell lymphoma of the penis: a case report and review of the literature]. Zhonghua Nan Ke Xue; 2008 Nov;14(11):1003-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary peripheral T-cell lymphoma of the penis: a case report and review of the literature].
  • OBJECTIVE: To report a case of primary peripheral T-cell lymphoma of the penis.
  • METHODS: We analyzed the clinicopathological characteristics of the case of primary peripheral T-cell lymphoma using histological, cytochemical and immunohistochemical methods and by review of the literature.
  • RESULTS: The patient was a 65 years old man and presented with a diffuse enlargement of the penis as the initial sign, followed by erosive ulcer in the caput penis and inguinal lymphadenectasis.
  • Clinically it responded to the chemotherapy designed for peripheral T-cell lymphoma.
  • CONCLUSION: Primary peripheral T-cell lymphoma of the penis is an extremely rare malignant tumor, the diagnosis of which relies on histopathological examination, immunohistochemical staining and differentiation between squamous cell carcinoma and other types of lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral. Penile Neoplasms

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102501.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M: Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol; 2008 Nov;88(4):434-40
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
  • Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction.
  • In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported.
  • Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine.
  • Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases.
  • The monoclonal B-cell population displayed EBV latency type III.
  • At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 microl(-1).
  • Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency.
  • We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / administration & dosage. Antibodies, Neoplasm / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Male. Middle Aged. Virus Latency / drug effects

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):16-24 [16758413.001]
  • [Cites] Annu Rev Immunol. 1997;15:405-31 [9143694.001]
  • [Cites] Clin Infect Dis. 2007 Jan 15;44(2):204-12 [17173218.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Transplantation. 2005 Oct 15;80(2 Suppl):S254-64 [16251858.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Leukemia. 2004 Mar;18(3):484-90 [14749699.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):87-91 [15982349.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1248-52 [15477211.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2 [14695424.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2412-8 [2822218.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):267-284 [6998005.001]
  • [Cites] Transpl Immunol. 2007 Apr;17(3):203-10 [17331848.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4059-66 [12829591.001]
  • [Cites] Blood. 2004 May 15;103(10):3979-81 [14751931.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1039-41 [18502831.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):3-12 [16371014.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1502-5 [10666232.001]
  • [Cites] Leuk Res. 1991;15(9):837-46 [1656151.001]
  • [Cites] Histopathology. 2005 Apr;46(4):464-6 [15810960.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1707-11 [17076535.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):733-9 [17672882.001]
  • [Cites] Am J Transplant. 2007 Jun;7(6):1648-55 [17511690.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Haematologica. 2008 Feb;93(2):e30-1 [18245646.001]
  • [Cites] Am J Transplant. 2007 Nov;7(11):2619-25 [17868060.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2 Suppl 2):S27-34 [16549112.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5748-55 [16115912.001]
  • (PMID = 18839273.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 04079A1RDZ / Cytarabine; 3A189DH42V / alemtuzumab
  •  go-up   go-down


48. Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K: IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leuk Lymphoma; 2005 Dec;46(12):1743-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.
  • The present study aimed to analyse the treatment outcome of IMVP-16/Pd (ifosfamide, methotrexate, etoposide and prednisone) followed by high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with peripheral T-cell lymphomas (PTCLs) who were previously treated with CHOP.
  • Since 1995, 32 PTCL patients were treated with IMPV-16/Pd.
  • Considering histopathologic subtypes, 3 of 4 relapsed natural killer (NK)/T-cell lymphoma patients (75%) achieved CR, but only 1 of 6 in non-NK/T-cell lymphoma patients (16.7%) achieved CR (P = 0.19).
  • These results indicate that IMVP-16/Pd followed by HDC/ASCT appears to be an effective salvage regimen, especially for NK/T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263576.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; IMVP-16 protocol
  •  go-up   go-down


49. Kojima H, Hasegawa Y, Suzukawa K, Mukai HY, Kaneko S, Kobayashi T, Kamoshita M, Shinagawa A, Komeno T, Komatsu T, Mitsuhashi S, Kawachi Y, Yamashita Y, Mori N, Nagasawa T: Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res; 2004 Dec;28(12):1287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification.
  • Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with "peripheral T-cell lymphoma, unspecified" diagnosed by the WHO criteria were reviewed.
  • Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin.
  • CR and PR were achieved in 12 and 10 out of 31 patients treated by CHOP-based chemotherapy, respectively.
  • Survival of CD4-/CD8+ cases, corresponding to cytotoxic T-cell lymphoma, was significantly worse than that of CD4+/CD8-.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Adult. Aged. CD4-CD8 Ratio. Classification. Female. Humans. Immunohistochemistry. Japan. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. T-Lymphocytes, Cytotoxic. Treatment Outcome. World Health Organization

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475070.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Ruco LP, Di Napoli A, Pilozzi E, Talerico C, Uccella I, Giancola ML, Alba L, Antinori A: Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients? AIDS Res Hum Retroviruses; 2004 Feb;20(2):129-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients?
  • Recently, a 15-fold increased risk of T cell lymphomas has been estimated in HIV-infected populations.
  • This increase has been observed for all T cell lymphoma subtypes.
  • In the present report we describe clinical and pathological features of three consecutive cases of peripheral T cell lymphoma (PTCL) with cytotoxic phenotype in HIV-positive patients that came to our attention in May-September 2002.
  • The diagnosis of PTCL was made in lymph node (two cases) and in needle biopsies from liver and bone marrow of the same patient.
  • The risk factor for each patient was heterosexual, injecting drug user, and homosexual, respectively.
  • CD4 cell counts were low (79-81 cells/mm3).
  • Two patients were naive for antiretroviral therapy.
  • At histological examination, all the involved tissues were effaced by a neoplastic proliferation of CD3+/CD8+ medium to large pleomorphic cells containing TIA-1+ cytotoxic granules and a few granzyme B+ granules.
  • Neoplastic cells were not infected by EBV or by HHV-8.
  • They were negative for the B cell antigens CD20 and CD79a, for CD30 and for CD56.
  • Clonal T cell receptor-g (TCR-g) rearrangements were demonstrated in the three cases.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15018699.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL: Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol; 2010 Jan;148(2):256-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
  • Romidepsin has shown promise in the treatment of T-cell lymphomas, and so we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health.
  • The endpoints included histone H3 acetylation and ABCB1 gene expression in peripheral blood mononuclear cells (PBMCs); ABCB1 gene expression in tumour biopsy samples; and blood fetal haemoglobin levels (HbF), all of which were increased following romidepsin treatment.
  • Histone acetylation in PBMCs at 24 h was associated with response (P = 0.026) as was the increase in fetal haemoglobin (P = 0.014); this latter association may be due to the longer on-study duration for patients with disease response.
  • Together, these results suggest that pharmacokinetics may be an important determinant of response to histone deacetylase inhibitors (HDIs) - the association with histone acetylation in PBMCs at 24 h is consistent with a hypothesis that potent HDIs are needed for a critical threshold of drug exposure and durable activity.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Depsipeptides / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / metabolism. P-Glycoprotein / metabolism. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 May;203(2):387-97 [15515013.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jul;314(1):467-75 [15833893.001]
  • [Cites] Mol Pharmacol. 2006 Jan;69(1):216-25 [16189296.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1547-55 [16533780.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):723-34 [16260035.001]
  • [Cites] Med Res Rev. 2006 Jul;26(4):397-413 [16450343.001]
  • [Cites] Am J Hematol. 2006 Dec;81(12):981-3 [16888791.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):804-10 [18245542.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):821-7 [18360709.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):170-6 [18510700.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6663-73 [18927309.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1287-93 [18948574.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Anticancer Drugs. 2000 Jul;11(6):445-54 [11001385.001]
  • [Cites] Ann Thorac Surg. 2001 Jan;71(1):295-301; discussion 301-2 [11216765.001]
  • [Cites] J Immunother. 2001 Mar-Apr;24(2):151-61 [11265773.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5 [11443220.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8492-7 [11731433.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):741-8 [17465197.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2781-90 [17179232.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1979-85 [17513804.001]
  • [Cites] Clin Pediatr (Phila). 2007 Jun;46(5):386-91 [17556734.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4916-21 [12208741.001]
  • [Cites] Leuk Res. 2002 Dec;26(12):1077-83 [12443879.001]
  • [Cites] Exp Hematol. 2003 Mar;31(3):197-203 [12644016.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2390-8 [12766035.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9231-42 [14647441.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1813-25 [15014036.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4636-43 [14996704.001]
  • [Cites] Cell. 1986 Nov 7;47(3):381-9 [2876781.001]
  • [Cites] J Biol Chem. 1989 Oct 25;264(30):18031-40 [2572588.001]
  • [Cites] Cancer Commun. 1990;2(10):345-55 [2206777.001]
  • [Cites] J Natl Cancer Inst. 1992 May 6;84(9):711-6 [1349044.001]
  • [Cites] Mol Pharmacol. 1994 Oct;46(4):627-38 [7969041.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4377-84 [9632821.001]
  • [Cites] Nat Med. 2005 Jan;11(1):71-6 [15619634.001]
  • [Cites] Cancer Invest. 2004;22(6):886-96 [15641487.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):177-82 [17579623.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7 [17875771.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • (PMID = 19874311.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antibiotics, Antineoplastic; 0 / Depsipeptides; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 9034-63-3 / Fetal Hemoglobin; CX3T89XQBK / romidepsin
  • [Other-IDs] NLM/ NIHMS180087; NLM/ PMC2838427
  •  go-up   go-down


52. Leung VK, Lin SY, Loke TK, Chau TN, Leung CY, Fung TP, Lam SH: Primary hepatic peripheral T-cell lymphoma in a patient with chronic hepatitis B infection. Hong Kong Med J; 2009 Aug;15(4):288-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic peripheral T-cell lymphoma in a patient with chronic hepatitis B infection.
  • We report a case of primary hepatic peripheral T-cell lymphoma in a patient with hepatitis B virus-related cirrhosis.
  • This patient presented with a solitary hepatic lesion with computed tomography and magnetic resonance imaging features that did not resemble hepatocellular carcinoma.
  • Subsequent biopsy of the lesion revealed that it was a peripheral T-cell lymphoma.
  • The patient was successfully treated with multi-agent chemotherapy followed by radiofrequency ablation.
  • Although hepatocellular carcinoma is the most frequently encountered primary hepatic tumour in patients with hepatitis B virus-related cirrhosis, primary hepatic lymphoma should also be borne in mind.
  • Nevertheless, primary hepatic lymphoma is a rare entity, and has no proven association with chronic hepatitis B infection.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652237.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS: Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol; 2009 Feb;88(2):111-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
  • The purpose of this retrospective study was to investigate clinical features and treatment outcomes in patients with peripheral T cell lymphoma-unspecified (PTCL-U).
  • Eighty-four patients who were diagnosed with PTCL-U between February 1995 and December 2005 were included in the study.
  • Around 70% of the patients presented with stage III-IV disease; 24% were categorized as high or high-intermediate risk according to the International Prognostic Index (IPI) scoring system, and 45% were classified as groups 3 or 4 using the Prognostic Index for PTCL-U (PIT).
  • Most of the initial chemotherapy regimens were anthracycline-based (75%).
  • The overall response rates for patients treated with initial chemotherapy and salvage chemotherapy were 63.1% (52.6% of complete response (CR), 10.5% of partial response (PR)) and 35% (9% of CR, 26%of PR), respectively.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648812.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Sato T, Kogawa K, Iyama S, Kobayashi D, Sato Y, Kuribayashi K, Takada K, Hagiwara S, Oku T, Takahashi S, Matsunaga T, Takahashi M, Terui T, Kato J, Niitsu Y: Successful treatment of advanced peripheral T-cell lymphoma with an angiocentric growth pattern complicated with hemophagocytic syndrome by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Ann Hematol; 2002 Dec;81(12):739-43
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of advanced peripheral T-cell lymphoma with an angiocentric growth pattern complicated with hemophagocytic syndrome by high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • Peripheral T-cell lymphomas (PTCL) account for about 10% of all lymphomas in Western countries, respond poorly to therapy, and have short survival with no sustained remission.
  • Furthermore, the complication of hemophagocytic syndrome (HPS) sometimes makes the prognosis of this disease extremely worse.
  • We report here a case of PTCL with an angiocentric growth pattern complicated with HPS successfully treated by high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • Our case suggests this approach is an excellent candidate for the treatment of this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytosis, Non-Langerhans-Cell / etiology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Carboplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Middle Aged. Remission Induction / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483373.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


55. Talpur R, Apisarnthanarax N, Ward S, Duvic M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma; 2002 Jan;43(1):121-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
  • Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas.
  • In general, their prognosis is poor, and specific therapy is not well defined.
  • We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK).
  • This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Aged. Erythema / etiology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymph Nodes / pathology. Male. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Receptors, Interleukin-2 / drug effects. Receptors, Interleukin-2 / metabolism. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908715.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21-CA74117
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


56. Gutiérrez A, Caballero MD, Pérez-Manga G, Rodriguez J: Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant; 2008 Dec;42(12):773-81
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic SCT for peripheral T-cell lymphoma.
  • Results of conventional chemotherapy for high-risk peripheral T-cell lymphoma (PTCL) are poor compared with those for their aggressive B-cell counterparts.
  • With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%).
  • From first frontline prospective clinical trials, it appears that ASCT is feasible and has a low TRM (<5%); consolidation in first complete response is associated with a very good outcome; around 25% of patients do not undergo ASCT due mainly to disease progression; new approaches aimed at increasing the number of chemosensitive patients should be found.
  • For all these mainly chemoresistant patients, there is preliminary evidence that allogeneic SCT (Allo-SCT) may produce a plateau in survival curves (with long-term PFS around 50%), which indicates a graft-versus-PTCL effect.
  • For this reason, Allo-SCT procedures are the object of ongoing clinical trials.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy. Salvage Therapy
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans. Remission Induction / methods. Survival Analysis. Transplantation Conditioning. Transplantation, Autologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936735.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Huang XC, Li XL, Huang RX, Jin XS: [Clinical characteristics and prognostic factors in 73 patients with peripheral T cell lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Feb;33(2):151-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognostic factors in 73 patients with peripheral T cell lymphoma].
  • OBJECTIVE: To investigate the clinical features,therapy and prognosis of patients with peripheral T cell lymphoma(PTCL), and to find out the prognostic factors of the disease.
  • METHODS: The clinical data of 73 patients with PTCL were reviewed.The median pre-treatment disease course was 3 months.Fifty-five patients were males, and 18 were females, with the median age of 42 years.Five patients received the combined chemo-radio therapy, 65 received chemotherapy alone, and the other 3 patients were treated with auto hematopoietic stem cell transplantation (HSCT).
  • RESULTS: Of all the patients, the overall 3 -year and 5-year survival rates were 38% (28 /73) and 22% ( 16 /73) respectively.The survival rates decreased with the progression of the Ann Arbor stages.The survival rate of the patients with B symptom (fever, night sweat, and weight loss) or the international prognostic factors index ( IPI)>2 was lower than those of the patients without B symptom or IPI<2.The patients with the increased CA125 or D-dimer lever had the worst curative effect.
  • CONCLUSION: Peripheral T cell lymphoma is highly aggressive with poor prognosis.The clinical features,Ann Arbor staging, IPI and B symptom are important prognostic factors.CA125 and D-dimer may be also important prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326910.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D
  •  go-up   go-down


58. Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y, Stein R, Zic J, Greer J: Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma; 2004 Nov;45(11):2261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant.
  • The role of high dose chemotherapy (HDC) and stem cell transplant (SCT) in peripheral T-cell lymphoma (PTCL) was studied in 28 patients, from 1988 to 2002.
  • The aim was to determine if subsets recognized by the REAL/WHO classification have different prognoses.
  • Outcome was compared to 86 patients with diffuse large B-cell lymphoma (DLBCL) transplanted during 1986-2000.
  • Patients with anaplastic large cell lymphoma (ALCL) had a better 3-year OS compared to those with non-ALCL histology (86% vs. 47%, P=0.0122).
  • Anaplastic lymphoma kinase (ALK)- positive ALCL patients had a superior EFS compared to ALK-negative ALCL (100% vs. 0; P=0.0228).
  • Low International Prognostic Index score at relapse predicted for a better 3-year OS (85% vs. 34%, P=0.0238).
  • When compared to DLBCL, patients with ALCL had a superior OS (86% vs. 36%, P=0.0034) and patients with non-ALCL had a comparable OS.
  • ALCL histology confers better survival compared to non-ALCL and DLBCL histologies.
  • The timing of SCT for non-ALCL histology remains to be determined.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Lymphoma, Large-Cell, Anaplastic / therapy. Male. Middle Aged. Prognosis. Protein-Tyrosine Kinases / biosynthesis. Receptor Protein-Tyrosine Kinases. Recurrence. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512815.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


59. Stark AM, Tiemann M, Dörner L, Melnikowa E, Mehdorn HM, Blömer U: Primary peripheral T-cell lymphoma of the central nervous system. Zentralbl Neurochir; 2004 Nov;65(4):191-4
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peripheral T-cell lymphoma of the central nervous system.
  • A 47-year-old man was admitted to our hospital with a nine-week history of visual disturbance, headache, disorientation and facial nerve palsy.
  • Open brain biopsy revealed primary central nervous system lymphoma of the extraordinary rare so-called "peripheral" T-cell type.
  • The further course was fatal; the patient died 10 weeks after the onset of symptoms from tumor progression before planned chemotherapy could be started.
  • CONCLUSION: If primary central nervous system lymphoma (PCNSL) is suspected, brain biopsy -- either open biopsy or stereotactic biopsy -- should be performed straight away to enable a rapid start of chemotherapy and/or radiotherapy.
  • Peripheral T-cell lymphoma was highly aggressive in this case leading to the patient's death within several weeks.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15551184.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Summers TA Jr, Rush W, Aguilera N, Lupton G: Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:25-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of a case and review of the literature.
  • Lennert lymphoma (LL), or the lymphoepithelioid variant of peripheral T-cell lymphoma, is an uncommon entity with rarely seen or reported presentations in the skin.
  • Cutaneous involvement of LL has been characterized by asymptomatic, non-ulcerated, red to violet papules, nodules and small plaques (less than 5 cm) on the trunk and extremities.
  • Key to the diagnosis of LL is the presence of epithelioid histiocytes and atypical small lymphoid cells without increased vascularity or epidermotropism.
  • Immunophenotyping shows a dense monoclonal T-cell population commonly associated with aberrant loss of T-cell-associated antigens.
  • T-cell receptor gene rearrangements are also identified.
  • Herein, we present a case of cutaneous involvement by LL at the time of initial presentation that persisted after initiation of chemotherapy and was finally verified as secondary cutaneous involvement of LL 1 year later histologically, immunophenotypically and by T-cell receptor gene rearrangement studies.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD / biosynthesis. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775391.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  • [Number-of-references] 18
  •  go-up   go-down


61. Tobinai K: Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol; 2010 Apr;47 Suppl 1:S5-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
  • The most common subtype of T-/natural killer (NK) cell lymphoma in Japan is adult T-cell leukemia-lymphoma (ATL), which is associated with the human T-cell lymphotropic virus type I (HTLV-1).
  • The investigators in Japan have conducted several clinical trials on multi-agent chemotherapy and stem cell transplantation for patients with ATL.
  • They have also initiated several new clinical trials with a number of agents: an anti-CCR4 antibody, KW-0761; forodesine, a purine nucleoside phosphorylase inhibitor; and lenalidomide, an immunomodulatory agent.
  • Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Drugs, Investigational / therapeutic use. Humans. Immunologic Factors / therapeutic use. Japan. Multicenter Studies as Topic. Purine Nucleosides / therapeutic use. Pyrimidinones / therapeutic use. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359583.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Drugs, Investigational; 0 / Immunologic Factors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 0 / mogamulizumab; 426X066ELK / forodesine; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Number-of-references] 9
  •  go-up   go-down


62. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • It has recently been demonstrated that AITLs originate from germinal center follicular helper T cells (TFH), whereas the normal counterparts of other PTCLs remain essentially unknown.
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • MATERIALS AND METHODS: One hundred forty-six PTCLs were analyzed for programmed death-1 (PD-1) expression in tissue microarrays using a new monoclonal antibody called NAT-105.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • Morphologic, clinical, and follow-up data were reviewed.
  • RESULTS: Twenty-five out of 87 non-AITL cases (28.75%) showed PD-1 immunostaining.
  • All cases expressed at least 2 TFH cell markers.
  • Of the remainder, 1 was considered to be early AITL, 1 was diagnosed as ALCL-anaplastic lymphoma kinase-negative, and 4 of the other 6 PTCLs-U had morphology consistent with lymphoepithelioid (Lennert's) lymphoma.
  • Our series of patients did not differ significantly in their clinical presentation from most reported PTCL cases in the literature: 55% of them were alive and 35% were in complete remission after a median follow-up of 15 months after cyclophosphamide, dexorubicin, vincristine, and prednisone-based chemotherapy.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • This suggests that the spectrum of AITL may be wider than previously thought, possibly including cases of lymphoepithelioid (Lennert's) lymphoma.
  • Additionally, the results suggest that a subgroup of PTCLs-U, distinct from AITL and including some cases denominated as ALCL, may also be derived from TFH cells, although they develop along a distinct pathogenic pathway.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


63. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol; 2007 Apr;18(4):652-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.
  • BACKGROUND: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas associated with poor prognosis with standard chemotherapy.
  • Consolidation with autologous stem-cell transplantation (ASCT) may improve survival.
  • We present 74 patients transplanted in first complete response (CR) from the Spanish Lymphoma and Autologous Transplantation Group cooperative group.
  • Eighty-eight percent presented advanced (III-IV) Ann Arbor stage; 53% had B symptoms; 52% had high lactate dehydrogenase; 65% had two or three risk factors of the adjusted-International Prognostic Index; 58% presented a high Tumor score and in 14% more than two adverse factors of the Prognostic Index for peripheral T-cell lymphoma (PIT) were observed.
  • RESULTS: With a median follow-up of 67 months from diagnosis, the 5-year overall survival (OS) was 68% and progression-free survival (PFS) reached 63%.
  • The multivariate analysis showed that the only factor associated with a shorter OS and PFS was the presence of more than two risk factors from the PIT risk system.
  • CONCLUSIONS: In a retrospective study with a prolonged follow-up, consolidation with ASCT in CR patients who had presented unfavorable prognostic factors at diagnosis substantially increased the OS and PFS when compared with conventional chemotherapy.
  • Thus, other innovative therapies are still necessary in certain cases.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229774.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Kahl C, Leithäuser M, Wolff D, Steiner B, Hartung G, Casper J, Freund M: Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol; 2002 Nov;81(11):646-50
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
  • Peripheral T-cell lymphomas (PTCL) are a rare entity of non-Hodgkin's lymphomas (NHL).
  • Despite the poor outcome after conventional chemotherapy, the impact of high-dose chemotherapy (HDCT) and autologous or allogeneic stem cell transplantation is not well defined in these patients.
  • In a retrospective study, we evaluated the outcome of 15 patients (9 male, 6 female) with PTCL after HDCT with autologous (10 patients) and allogeneic (5 patients) stem cell transplantation between 1996 and 2001 at our department.
  • At the time of transplantation three patients were in second remission, seven patients were in partial remission (PR), and three patients had refractory disease.
  • After HDCT ten patients (67%, autologous 7, allogeneic 3) achieved CR, two patients (13%, autologous 2, allogeneic 0) had refractory disease, and three patients (20%, autologous 1, allogeneic 2) died because of toxic side effects before evaluation of response was performed.
  • At the time of evaluation, six patients are alive and nine patients have died (four severe infection, one late toxicity, two disease progression, and two relapse).
  • Despite the small number of patients in this study, HDCT with autologous or allogeneic hematopoietic transplantation seems to be an effective treatment option that can achieve CR for patients with PTCL.
  • Because of the poor outcome of these patients after conventional chemotherapy, HDCT seems to be a rational option in first-line therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Cause of Death. Female. Humans. Male. Retrospective Studies. Survival Analysis. Transplantation, Autologous / methods. Transplantation, Autologous / mortality. Transplantation, Homologous / methods. Transplantation, Homologous / mortality. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12454703.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Sanchez S, Holmes H, Katabi N, Newman J, Domiatti-Saad R, Stone M, Netto G: Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature. Arch Pathol Lab Med; 2006 Jan;130(1):107-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature.
  • We report a case of a 65-year-old black man with combined Hodgkin lymphoma and T-cell lymphoma.
  • Subsequent biopsy of an axillary lymph node revealed a composite lymphoma composed of classic Hodgkin lymphoma and a peripheral T-cell lymphoma.
  • A needle biopsy of the liver also showed involvement by the composite lymphoma.
  • Development of T-cell lymphoma following chemotherapy for Hodgkin lymphoma has been reported, but synchronous composite occurrence of both lesions is very rare.
  • We present a review of the literature and a discussion of the potential pathophysiologic role of Epstein-Barr virus in the early stages of T-cell lymphomagenesis.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / pathology. Lymphocytes / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390224.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


66. Murdoch F, Chien PF, Evans AT: Primary peripheral T cell lymphoma of the endometrium. J Clin Pathol; 2001 Jan;54(1):74-5
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peripheral T cell lymphoma of the endometrium.
  • A case of a primary peripheral T cell lymphoma arising in the endometrium is presented.
  • Primary lymphomas of the female genital tract are rare, with endometrial lymphomas and those of T cell type being rarer still.
  • Extensive investigations revealed no other sites of disease and the patient was treated by hysterectomy and chemotherapy.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11271794.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1731268
  •  go-up   go-down


67. Uemura Y, Imai T, Nakajim T, Urata T, Doi H: [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):28-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
  • Pathological examination of the esophagus biopsy specimens showed an unspecified peripheral T cell lymphoma.
  • The esophagus tumor was tolerant to CHOP and EPOCH therapy.
  • After an autologous peripheral blood stem cell transplantation, a complete response was observed in the patient.
  • However, a lymphoma relapse was diagnosed in the lung in September 2008.
  • The relapsed lung lymphoma was tolerant to EPOCH therapy.
  • The refractory pulmonary peripheral T cell lymphoma was remarkably reduced by PEGS therapy.
  • PEGS therapy is useful for relapsed peripheral T cell lymphoma cases that tolerated standard chemotherapy.
  • An allogenic hematopoietic stem cell transplantation or new molecular target therapy might be finally selected for refractory peripheral T cell lymphoma.
  • Furthermore we could not easily try phase I or II new molecular target drug treatment.
  • We think that PEGS therapy is a useful treatment for refractory peripheral T cell lymphoma before allogenic transplantation or new molecular target drug treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163018.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0W860991D6 / Deoxycytidine; 5GMR90S4KN / Methylprednisolone Hemisuccinate; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E: Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica; 2007 Feb;92(2):271-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
  • Novel, effective therapies are needed for peripheral T-cell non-Hodgkin's lymphoma (PTCL).
  • We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone (GEM-P).
  • GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Peripheral / drug therapy. Methylprednisolone / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296587.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


69. Shirai T, Takahashi R, Tajima Y, Kohata K, Yamamoto J, Fujii H, Takasawa N, Ishizawa K, Ichinohasama R, Ishii T, Harigae H: Peripheral T cell lymphoma with a high titer of proteinase-3-antineutrophil cytoplasmic antibodies that resembled Wegener's granulomatosis. Intern Med; 2009;48(23):2041-5
MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T cell lymphoma with a high titer of proteinase-3-antineutrophil cytoplasmic antibodies that resembled Wegener's granulomatosis.
  • Together with the findings of MRI, a diagnosis of WG was made.
  • However, the disease progressed rapidly and histological examination of the second biopsy revealed infiltration of neoplastic T lymphocytes with aberrant loss of CD7.
  • A final diagnosis of peripheral T cell lymphoma, not otherwise specified (WHO) was made, and complete remission was achieved by chemotherapy.
  • This is a very rare case of T cell lymphoma with a high titer of PR3-ANCA.
  • [MeSH-major] Antibodies, Antineutrophil Cytoplasmic / blood. Granulomatosis with Polyangiitis / blood. Granulomatosis with Polyangiitis / diagnosis. Lymphoma, T-Cell, Peripheral / blood. Lymphoma, T-Cell, Peripheral / diagnosis. Myeloblastin / blood
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952489.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic; EC 3.4.21.76 / Myeloblastin
  •  go-up   go-down


70. Eum EA, Kim H, Kim YM, Woo SJ, Cho JH, Min YJ, Park JH: Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient. Korean J Intern Med; 2006 Dec;21(4):262-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient.
  • Anorectum is a rare location for malignant lymphoma.
  • Involvement of is rare even for the lynphoma associated with acquired immune deficiency syndrome (AIDS), and AIDS has a relatively increased frequency of anorectal lymphoma.
  • Most lymphomas in AIDS patients are of a B-cell origin, and T-cell lymphoma of the gastrointestinal tract is extremely rare.
  • We report here on a case of anorectal and gastric peripheral T-cell lymphoma, unspecified (PTCLu) in a non-AIDS patient.
  • He underwent excisional biopsy for the anal mass and the diagnosis was PTCLu.
  • Biopsies of the gastric lesions gave the same diagnosis.
  • There was no lymphoma involved in the bone marrow.
  • He underwent systemic chemotherapy and upfront autologous stem cell transplantation.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Lymphoma, T-Cell, Peripheral / pathology. Rectal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Follow-Up Studies. Gastroscopy. Humans. Male. Sigmoidoscopy. Tomography, X-Ray Computed


71. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T, Fukuoka Blood and Marrow Transplantation Group: Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant; 2010 Feb;45(2):311-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
  • Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma.
  • To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005.
  • Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified.
  • Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients.
  • Rapid engraftment was obtained in all cases, and transplant-related death was not seen.
  • An estimated 5-year OS was 62.1% with a median follow-up of 78 months.
  • The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P=0.046).
  • HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Japan / epidemiology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597416.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant; 2007 Aug;40(3):239-43
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
  • The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined.
  • Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL.
  • Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL.
  • In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen.
  • Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease.
  • These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530000.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


73. Matano S, Shirasaki H, Terahata S, Nobata K, Sugimoto T: Thickening of multiple cranial nerves in a patient with extranodal peripheral T-cell lymphoma. J Neuroimaging; 2006 Apr;16(2):167-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thickening of multiple cranial nerves in a patient with extranodal peripheral T-cell lymphoma.
  • A 57-year-old male became aware of a subcutaneous tumor in March 2001.
  • Histopathological examination showed peripheral T-cell lymphoma.
  • He achieved complete remission after chemotherapy.
  • Later the lymphoma relapsed in the subcutaneous lesion and chemotherapy was performed again.
  • In April 2003, he developed diplopia, dysarthria, and dysphagia.
  • Cranial magnetic resonance imaging did not detect any intraparenchymal lesions, but thickening of multiple cranial nerves was detected.
  • After intrathecal chemotherapy, atypical cells disappeared from the cerebrospinal fluid and thickening of the cranial nerves was resolved.
  • Finally, lymphoma spread to the bone marrow, and the patient died in July 2003.
  • [MeSH-major] Cranial Nerves / pathology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Bone Marrow Neoplasms / secondary. Contrast Media. Fatal Outcome. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629741.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


74. Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE: New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res; 2010 Dec 1;16(23):5608-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
  • Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas.
  • They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas.
  • Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy.
  • In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / etiology. Lymphoma, T-Cell, Peripheral / therapy. Therapies, Investigational / trends
  • [MeSH-minor] Animals. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Cell Biology. Comprehension. Drug Discovery / methods. Drug Discovery / trends. Gene Expression Profiling. Humans. Molecular Targeted Therapy / methods

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):924-32 [16467107.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169 [16520806.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Blood. 2006 Jul 15;108(2):705-10 [16551968.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):746-55 [17234786.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34 [17406867.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):521-5 [17454592.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):348-53 [17534160.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2764-9 [17515574.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1836-8 [18661402.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] Bone Marrow Transplant. 2008 Dec;42(12):773-81 [18936735.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2514-22 [19293260.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4307-12 [11110706.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):185-7 [11328299.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2744-54 [12855655.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3737-42 [12881320.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):342-9 [14716770.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Br J Haematol. 2009 Jul;146(2):171-9 [19466965.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] Am J Health Syst Pharm. 2009 Nov 1;66(21):1890 [19850775.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] Leukemia. 2010 Jan;24(1):229-32 [19776763.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):256-67 [19874311.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):447-55 [20141439.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1591-8 [20177026.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):860-3 [19887465.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2578-85 [19965662.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):602-6 [2783489.001]
  • [Cites] Cell. 1992 Feb 7;68(3):421-7 [1310894.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5335-41 [7585597.001]
  • [Cites] Blood. 1996 Jan 1;87(1):284-91 [8547653.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1367-72 [9264394.001]
  • [Cites] Blood. 1998 Jan 15;91(2):399-405 [9427692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1351-3 [9932168.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • (PMID = 21138864.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS236831; NLM/ PMC3058794
  •  go-up   go-down


75. Chen AI, Advani RH: Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. J Natl Compr Canc Netw; 2008 Apr;6(4):428-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
  • Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis.
  • Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL.
  • Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports.
  • Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL.
  • This article reviews promising novel approaches in the treatment of PTCL and its subtypes.
  • Investigation into the pathogenesis of PTCL has also identified new targets for treatment.
  • These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma.
  • These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings.
  • Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms.
  • These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Diphtheria Toxin / therapeutic use. Histone Deacetylase Inhibitors. Humans. Immunosuppressive Agents / therapeutic use. Interleukin-2 / therapeutic use. Practice Guidelines as Topic. Protease Inhibitors / therapeutic use. Purine Nucleosides / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. Pyrimidinones / therapeutic use. Recombinant Fusion Proteins / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433608.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Diphtheria Toxin; 0 / Histone Deacetylase Inhibitors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Protease Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / zanolimumab; 0W860991D6 / Deoxycytidine; 25E79B5CTM / denileukin diftitox; 3A189DH42V / alemtuzumab; 426X066ELK / forodesine; 60158CV180 / nelarabine; B76N6SBZ8R / gemcitabine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


76. O'Connor OA: Novel agents in development for peripheral T-cell lymphoma. Semin Hematol; 2010 Apr;47 Suppl 1:S11-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents in development for peripheral T-cell lymphoma.
  • Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease.
  • A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are noticeably absent.
  • Combinations of T-cell centric agents could produce novel platforms of therapy to replace the relatively ineffective CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimens.
  • Among agents with T-cell activity are the folate analog pralatrexate, histone deacetylase inhibitors (HDACi) like romidepsin, the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the purine nucleoside phosphorylase (PNP) inhibitor forodesine, the nucleoside analog gemcitabine, and BH3-only mimetics like ABT-263 and ABT-737.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Aminopterin / analogs & derivatives. Aminopterin / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Clinical Trials as Topic. Depsipeptides / therapeutic use. Drug Design. Histone Deacetylase Inhibitors / therapeutic use. Humans. Immunologic Factors / therapeutic use. Purine Nucleosides / therapeutic use. Pyrazines / therapeutic use. Pyrimidinones / therapeutic use. Salvage Therapy. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Inc.
  • (PMID = 20359580.001).
  • [ISSN] 1532-8686
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Depsipeptides; 0 / Drugs, Investigational; 0 / Histone Deacetylase Inhibitors; 0 / Immunologic Factors; 0 / Purine Nucleosides; 0 / Pyrazines; 0 / Pyrimidinones; 426X066ELK / forodesine; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; CX3T89XQBK / romidepsin; F0P408N6V4 / lenalidomide; JYB41CTM2Q / Aminopterin
  • [Number-of-references] 24
  •  go-up   go-down


77. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K, Kyushu Hematology Organization for Treatment Study Group (K-HOT): THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol; 2010 May;84(5):391-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
  • OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.
  • The subset analysis showed that T-cell lymphoma had a significantly better response with THP-COP, whereas no such difference was observed in B-cell lymphoma.
  • The aim of this study is to confirm the efficacy of THP-COP in the treatment of T-cell lymphoma.
  • METHODS: We underwent a multicenter phase II study of THP-COP as a first-line treatment for T-cell lymphoma.
  • Seventeen patients had peripheral T-cell lymphoma (PTCL), including nine of PTCL not otherwise specified (PTCL-NOS) and eight of angioimmunoblastic T-cell lymphoma (AITL).
  • Thirty-six patients had adult T-cell leukemia/lymphoma (ATLL), including 20 of acute type and 16 of lymphoma type.
  • A treatment response was obtained in 35 (66%) patients, including 17 (32%) complete responses.
  • Median overall survival (OS) and progression-free survival (PFS) times were 14.3 months and 5.2 months, respectively.
  • Patients with ATLL showed a tendency to obtain low response rate (61% vs. 77%, P = 0.27) and had a significantly inferior OS (13.3 vs. 28.6 months, P = 0.04) and PFS (4.6 vs. 8.1 months, P = 0.01) in comparison with PTCL.
  • Febrile neutropenia was observed in 51% and grade 3 non-hematological toxicities in 2-9% of the patients.
  • CONCLUSION: The efficacy of THP-COP is equivalent to that of CHOP for the first-line therapy in T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059527.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


78. Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer; 2010 Feb;54(2):212-5
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
  • BACKGROUND: Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.
  • PROCEDURE: We performed a retrospective analysis in patients with PTCL over an 18-year period (1991-2008).
  • RESULTS: We could analyze clinical data in 21 patients with non-anaplastic PTCL; 10 were female and 10 male.
  • There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma.
  • In five patients, hemophagocytic syndrome (HPS) was the initial clinical feature.
  • There were 12 patients with advanced stage disease (stages III and IV).
  • Chemotherapy and radiation was administered in 18 and 2 patients, respectively.
  • Among the two patients who did not receive chemotherapy and radiation, one patient died while being treated for HPS but another improved spontaneously.
  • Although 5 patients relapsed, 18 of 21 patients remained alive without disease at last follow-up.
  • CONCLUSIONS: Generally, the outcome results of conventional chemotherapy for high-risk PTCL are poor in adult patients.
  • However, the excellent results in our study suggest that PTCL of childhood is quite different from that of adulthood.
  • Although this study is first report about PTCL of Asian children, the number of patients was small in this study.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / epidemiology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan / epidemiology. Male. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19856396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Rosenberg B: Peripheral T-cell lymphoma. Dermatol Online J; 2005;11(4):5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma.
  • A 32-year-old man presented with a 5-year history of cutaneous nodules on his head and a diffuse, lichenified eruption.
  • Immunophenotyping studies determined that the lymphocyte population to be CD4-positive, with partial loss of CD3 and CD7, and immunogenotyping studies showed a clonal rearrangement of the T-cell receptor.
  • A positron-emission tomography scan showed increased uptake in cervical, axillary, and inguinal lymph nodes.
  • A diagnosis of peripheral T-cell lymphoma was made, and the patient is undergoing chemotherapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403377.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zapletalova J, Langova K: Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):103-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.
  • BACKGROUND: Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas.
  • The clinical course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years.
  • Published data are limited to retrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes.
  • AIM: To evaluate the current treatment modalities, clinical outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic).
  • METHOD: Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000.
  • RESULTS: We analyzed 63 patients with new diagnosis of PTCL-US.
  • The median age was 59 years (25-81), chemotherapy (CHT) was administered in 56 of the 63 patients: anthracyclin-based CHT in 51%, intensive CHT in 21% and non-anthracyclin regimen was applied in 13% of the patients.
  • After a median follow-up of 19.6 months, 41% of the patients were in CR, 3.4% in PR or stable disease and 55% of the patients died.
  • Clinical stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis.
  • CONCLUSIONS: Although the current treatment modalities are mostly ineffective in PTCL-US, appropriate intensive treatment may lead to prolonged remission but not survival.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690750.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


81. Huang Z, Higgins B, Foss F: Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma; 2005 Jun;6(1):43-5
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of gallium nitrate in refractory peripheral T-cell lymphoma.
  • Peripheral T-cell lymphomas (PTCLs) are post-thymic malignancies characterized by an aggressive clinical course and an inferior outcome with standard therapies.
  • The authors report significant clinical activity of infusional gallium nitrate in a patient with stage IV PTCL disease refractory to chemotherapy.
  • [MeSH-major] Gallium / therapeutic use. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Humans. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989706.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 13494-90-1 / gallium nitrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


82. Said J, Pinter-Brown L: Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion. Clin Adv Hematol Oncol; 2009 Nov;7(11):S1, S4-13; quiz S15
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion.
  • The diverse group of peripheral T-cell lymphomas (PTCLs) present clinical and pathologic challenges.
  • Proper recognition and diagnosis can be difficult even for experienced pathologists because these entities tend to vary in morphologic appearance from case to case within the same subtype and often mimic other diseases in appearance.
  • Clinically, PTCLs are difficult to treat because they often present in an advanced stage and are resistant to traditional first-line chemotherapeutic regimens.
  • Five-year overall survival rates are dismal, ranging from 20-50%, depending upon subtype.
  • Although high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation has been reported to improve overall survival in patients with PTCL, this therapy is only feasible for the small minority of patients who experience a durable complete response to induction therapy.
  • In this monograph, 2 case studies of different subtypes of PTCL will be presented, and the clinical and pathologic features will be discussed.
  • In addition, data on emerging therapies for PTCLs will be reviewed with an emphasis on novel and investigational agents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095101.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma; 2010 Mar;51(3):447-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
  • The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable.
  • Therefore, there is a need for improvement of treatment options.
  • Patients with newly diagnosed (n = 27) or refractory/relapsed (n = 11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin.
  • The overall response rate (ORR) was 61%, with a complete response rate of 39%.
  • Cytomegalovirus (CMV) reactivation occurred in 12 patients, but only two had CMV disease.
  • Treatment-related deaths occurred in six newly diagnosed patients and one with relapsed/refractory disease.
  • In conclusion, Campath-FCD is active in PTCL but is associated with significant toxicity and is, therefore, not recommended for use or further study.
  • Further studies are warranted to investigate other approaches to combining alemtuzumab with chemotherapy for the treatment of PTCL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, T-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Treatment Outcome

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141439.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


84. Mitarnun W, Saechan V, Pradutkanchana J, Suwiwat S, Takao S, Ishida T: Epstein-Barr virus-associated peripheral T-cell lymphoma with gastrointestinal tract involvement. J Med Assoc Thai; 2003 Sep;86(9):816-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated peripheral T-cell lymphoma with gastrointestinal tract involvement.
  • Peripheral T-cell lymphoma (PTCL) is a group of diseases which are common in Asia and areas of South and Central America.
  • In the present study the authors evaluated patients with gastrointestinal involvement of PTCL with respect to clinical findings and outcome, pathologic features, and molecular analysis for EBV infection and the clonality of tumor cells.
  • From January 1997 through December 2000, 7 patients with gastrointestinal tract involvement of PTCL were identified.
  • The frequency of gastrointestinal tract involvement in the various types of PTCL was 5.4 per cent (7 of 129 cases).
  • The pertinent clinical features were prolonged fever, weight loss, anemia, hepatosplenomegaly, lymphadenopathy, multiorgan involvement, and gastrointestinal bleeding.
  • Five patients died within 4 months after onset of illness, while two were in complete remission after chemotherapy.
  • The tumor cell morphology was classified into three categories: small-sized cells, mixed medium- and large-sized cells, and large-sized cells.
  • EBV-RNA expression by in situ hybridization (EBER-ISH) study was positive and T-cell receptor (TCR) beta and/or gamma gene rearrangements were detected in all patients.
  • PTCL with gastrointestinal tract involvement was associated with EBV infection.
  • The tumor cells were mature T cells with some NK-cell antigenic expression and all demonstrated TCR gene rearrangements.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Gastrointestinal Neoplasms / epidemiology. Lymphoma, T-Cell, Peripheral / epidemiology
  • [MeSH-minor] Adult. Comorbidity. Female. Genes, T-Cell Receptor / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Male. Prospective Studies. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14649966.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


85. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol; 2010 Mar 20;28(9):1591-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
  • This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL).
  • RESULTS: Fifteen patients completed the protocol treatment.
  • Only one patient, at the 1.0 mg/kg dose, developed grade 3 dose-limiting toxicities, skin rash, and febrile neutropenia, and grade 4 neutropenia.
  • Other treatment-related grade 3 to 4 toxicities were lymphopenia (n = 10), neutropenia (n = 3), leukopenia (n = 2), herpes zoster (n = 1), and acute infusion reaction/cytokine release syndrome (n = 1).
  • The maximum tolerated dose was not reached.
  • CONCLUSION: KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL.
  • [MeSH-major] Antibodies, Anti-Idiotypic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy. Receptors, CCR4 / antagonists & inhibitors
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Aug 10;28(23):e404-5; author reply e406 [20566994.001]
  • (PMID = 20177026.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Receptors, CCR4; 0 / mogamulizumab
  •  go-up   go-down


86. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • We conducted a retrospective review of patients who underwent AHCT for PTCL from 1989 to 2006.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Fifteen patients were transplanted in first complete or partial response (CR1/PR1), 32 in second or beyond CR or PR (CR2/PR2+), and 11 with primary refractory disease (REF).
  • With a median follow-up was 5 years (range: 1.0-11.5), the 5-year progression-free survival (PFS) and overall survival (OS) were 25% and 48%, respectively.
  • Disease status at AHCT had a significant impact on PFS and OS.
  • The pretransplant factors that impacted survival were disease status and the number of prior regimens.
  • Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.
  • Based on these results, AHCT as consolidation therapy in first complete or partial response may offer a durable survival benefit.
  • However, AHCT with conventional salvage chemotherapy has minimal durable benefit in patients with relapsed or refractory PTCL, and thus novel strategies and/or allogeneic HCT should be more aggressively explored in lieu of AHCT for relapsed/ refractory PTCL.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • (PMID = 18541192.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-15; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-15
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232367; NLM/ PMC2980839
  •  go-up   go-down


87. Xue LJ, Mao XB, Liu XB, Su QS, Yu HJ, Yang JH: Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy. Case Rep Med; 2010;2010:403237
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy.
  • Peripheral T-cell lymphoma (PTCL) is rare and difficult to treat for its high relapse rate.
  • The authors report a case of PTCL of the skin, regarding which clinical and pathological features, treatment, and prognosis were discussed.
  • Surgical resection of right leg lesion and biopsy of enlarged inguinal lymph nodes histologically indicated a PTCL of the nasal type.
  • The patient was treated by CHOP plus bortezomib, reached complete remission just after two courses of chemotherapy and then received another two as consolidation.
  • As for cutaneous lesions, detailed lymph node examination and prompt tissue biopsy are judicious choices prior to any medical management.
  • The chemotherapy consisting of bortezomib and CHOP is safe and efficient in PTCL of the skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Dermatology. 1997;194(3):268-72 [9187846.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):618-25 [15033670.001]
  • [Cites] Drug Resist Updat. 2008 Aug-Oct;11(4-5):164-79 [18818117.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):715-21 [19150954.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2354-63 [16219794.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Blood Rev. 2007 Jul;21(4):201-16 [17512649.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Ann Hematol. 2008 Dec;87(12):1023-4 [18587577.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):111-9 [18648812.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • (PMID = 21209804.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3014791
  •  go-up   go-down


88. Aoki K, Kotani S, Ichinohe T, Kondo T, Ishikawa T: Acute renal failure associated with systemic polyoma BK virus activation in a patient with peripheral T-cell lymphoma. Int J Hematol; 2010 Nov;92(4):638-41
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure associated with systemic polyoma BK virus activation in a patient with peripheral T-cell lymphoma.
  • Renal dysfunction associated with polyoma BK virus (BKV) reactivation usually occurs in the setting of profound immunosuppression related to renal transplantation and hematopoietic stem cell transplantation.
  • However, it has been rarely described as a complication during the course of conventional chemotherapy.
  • Here, we report a case of BKV-associated acute renal failure developed in a patient suffering from refractory peripheral T-cell lymphoma, not otherwise specified.
  • After repetitive cycles of salvage chemotherapy, the patient developed fever and urinary frequency, rapidly followed by anuria that necessitated the emergent institution of hemodialysis.
  • High levels of BKV were detected in urine and plasma with quantitative real-time polymerase chain reaction, strongly suggesting that his renal failure was due to polyoma virus-associated nephropathy.
  • This rare complication should be kept in mind in case of unexplained renal failure developed in immunodeficient patients undergoing cytotoxic chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. BK Virus / physiology. Lymphoma, T-Cell, Peripheral / complications. Polyomavirus Infections / complications. Tumor Virus Infections / complications. Virus Activation
  • [MeSH-minor] Humans. Immunosuppression / adverse effects. Male. Middle Aged. Salvage Therapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2006 Mar 15;81(5):704-10 [16534472.001]
  • [Cites] J Clin Virol. 2009 Aug;45(4):341-4 [19477682.001]
  • [Cites] Transplantation. 2007 Aug 15;84(3):340-5 [17700158.001]
  • [Cites] J Med Virol. 1982;10(2):91-9 [6292361.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1762-7 [14630682.001]
  • [Cites] Transplantation. 2003 Jan 15;75(1):105-12 [12544881.001]
  • [Cites] Am J Hematol. 2009 Apr;84(4):243-6 [19208419.001]
  • [Cites] Rinsho Ketsueki. 1994 Jul;35(7):635-41 [8065017.001]
  • [Cites] Lancet Infect Dis. 2003 Oct;3(10):611-23 [14522260.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1573-82 [7687667.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):528-37 [15712075.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):527-30 [12181409.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] J Pediatr. 2007 Aug;151(2):215-7 [17643782.001]
  • [Cites] Transplantation. 2006 Jul 27;82(2):292-3 [16858298.001]
  • [Cites] Transplantation. 2008 Mar 27;85(6):850-4 [18360267.001]
  • (PMID = 20924732.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Zain JM, O'Connor O: Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol; 2010 Jul;92(1):33-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted treatment and new agents in peripheral T-cell lymphoma.
  • Mature T-cell and NK-cell lymphomas are increasingly being recognized as unique biological entities distinguishable from other forms of lymphomas.
  • Treatment paradigms developed for B-cell lymphomas are considered inadequate for application to these diseases, as indicated by the poor outcome of these patients with the overall 5-year survival remaining below 30% for most histologies.
  • There is a tremendous need for newer treatment options both in the upfront and relapsed setting for T-cell lymphomas.
  • In recent years, there has been a plethora of new targeted agents that have shown promising activity in T-cell lymphomas.
  • The most notable is the novel antifolate pralatrexate that has been approved for the treatment of relapsed and refractory T-cell lymphoma.
  • An improved understanding of the molecular pathogenesis of T-cell lymphomas will help define the role of these agents in the treatment paradigms of T-cell lymphomas both as single agents and as rationally designed combinations and will lead to curative treatments for these difficult diseases.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems / methods. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Disease-Free Survival. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Hematol Oncol. 2009 Oct 27;2:45 [19860903.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):313-8 [9744777.001]
  • [Cites] Cancer Sci. 2009 Feb;100(2):341-8 [19068089.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):13-8 [12892709.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(1):18-25 [6690069.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9 [19221750.001]
  • [Cites] Cancer Invest. 2000;18(7):609-13 [11036468.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):166-73 [16330674.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Med Chem. 1993 Jul 23;36(15):2228-31 [8340923.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):779-84 [11157031.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3421-8 [18451170.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1247-52 [17962618.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6217-24 [19789316.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2906-16 [18591385.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Blood. 2006 Jul 1;108(1):382-9 [16522821.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96 [17628529.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3971-93 [15897549.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2437-41 [16216001.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):170-6 [18510700.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6383-91 [17616698.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Cancer Cell. 2004 May;5(5):417-21 [15144949.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3493-8 [10999734.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):121-6 [11908715.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Leukemia. 2003 Jan;17(1):41-4 [12529658.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • (PMID = 20535594.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


90. Murakami T, Ohtsuki M, Nakagawa H: Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile. Br J Dermatol; 2001 Apr;144(4):878-84
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile.
  • Angioimmunoblastic T-cell lymphoma is a type of peripheral T-cell lymphoma that is clinically characterized by high fever and generalized lymphadenopathy with or without cutaneous involvement.
  • Immunohistochemical studies indicated that the neoplastic cells were mature CD4+ T lymphocytes.
  • Southern blot analysis detected a clonal expansion of T-cell receptor beta.
  • Based on these findings, a diagnosis of angioimmunoblastic T-cell lymphoma with cutaneous infiltration was made.
  • Despite systemic chemotherapy, the disease exhibited a high level of activity and continued on a fatal course.
  • An analysis of gene expression profiling using complementary DNA microarrays revealed significant expression of some chemokines and cytokines, e.g. secondary lymphoid tissue chemokine, macrophage inflammatory protein (MIP)-1beta, MIP-3alpha, MIP-3beta, B-lymphocyte chemokine, interleukin-16 and tumour necrosis factor-beta, and an apoptosis-inhibitory protein (FLICE inhibitory protein) in the affected lymph nodes.
  • Profiling of gene expression patterns for a variety of genes in additional cases may be helpful in determining which factors predict the biological and clinical behaviour of angioimmunoblastic T-cell lymphoma or other aggressive malignant lymphomas.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Skin / pathology
  • [MeSH-minor] Cytokines / genetics. Cytokines / metabolism. Fatal Outcome. Gene Expression. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298554.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


91. Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B: Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma; 2010 Oct;51(10):1822-8
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
  • Peripheral T-cell lymphoma, unspecified (PTCLU) is the most common T-cell lymphoma variant.
  • The molecular heterogeneity of PTCLU is reflected by a diverse clinical course.
  • Sixty-nine cases with a pathological diagnosis of PTCLU were included in our analysis.
  • Lymphopenia was seen in 38% of the patients and was statistically associated with a worse response to chemotherapy.
  • In univariate analysis, lymphopenia, IPI score>2, and Prognostic Index for PTCLU (PIT) score>2 were associated with a worse overall survival.
  • In multivariate analysis, lymphopenia and a PIT score>2 were the only independent poor prognostic factors, implying an important role of the patient's immune system in both response to therapy and survival.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Lymphopenia / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphocyte Count. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Oct;51(10):1773-4 [20849382.001]
  • (PMID = 20849388.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Kimby E: Management of advanced-stage peripheral T-cell lymphomas. Curr Hematol Malig Rep; 2007 Oct;2(4):242-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced-stage peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCLs), several entities with great clinical, histologic, and biologic heterogeneity, represent 8% to 15% of all malignant lymphomas.
  • With current treatment regimens, 5-year survival is only about 30% to 35%.
  • Outcome is poorer with PTCL than with aggressive B-cell lymphoma because of more frequent adverse clinical features at diagnosis, a lower response rate to chemotherapy, and a higher incidence of relapses, but it is also known that the T-cell phenotype itself is associated with a poor prognosis independent of other prognostic factors.
  • Initial treatment of patients with advanced-stage PTCL mostly consists of six to eight courses of anthracycline-based chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
  • In fit elderly patients, standard therapy is still six cycles of CHOP-14, but up-front consolidation with intensive chemotherapy and autologous stem cell transplantation are often used in younger patients.
  • The humanized CD52 monoclonal antibody alemtuzumab has shown activity in some T-cell malignancies; with appropriate antibiotic and virostatic prophylaxis, its use seems feasible for PTCL, both as a single agent and in conjunction with chemotherapy.
  • New drugs such as denileukin diftitox, histone deacetylase inhibitors, and pralatrexate have shown promising activity in PTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Clinical Trials as Topic. Combined Modality Therapy. Drugs, Investigational / therapeutic use. Folic Acid Antagonists / therapeutic use. Glycoproteins / immunology. Histone Deacetylase Inhibitors / therapeutic use. Humans. Immunologic Factors / therapeutic use. Immunotherapy. Mice. Mice, Nude. Multicenter Studies as Topic. Retrospective Studies. Stem Cell Transplantation. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Leukemia. 2007 Feb;21(2):215-21 [17170730.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6 [16516670.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7 [17187516.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):591-7 [16988580.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):290-6 [17378891.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Cancer. 1976 Oct;38(4):1484-93 [791473.001]
  • [Cites] Hematol J. 2001;2(5):300-6 [11920265.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1991 Dec;8(6):503-6 [1790431.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1079-86 [10572606.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Ann Intern Med. 1992 Sep 1;117(5):364-70 [1380221.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):117-21 [17325855.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):521-5 [17454592.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1351-3 [9932168.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2 Suppl 2):S27-34 [16549112.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):271-3 [15937499.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • (PMID = 20425376.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Drugs, Investigational; 0 / Folic Acid Antagonists; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Immunologic Factors; 3A189DH42V / alemtuzumab
  • [Number-of-references] 53
  •  go-up   go-down


93. Huang HQ, Peng YL, Lin XB, Sun XF, Lin TY, Xia ZJ, Li YH, Cai QQ, He YJ, Jiang WQ, Guan ZZ: [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen]. Ai Zheng; 2004 Nov;23(11 Suppl):1443-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
  • BACKGROUND & OBJECTIVE: T-cell Non-Hodgkin's lymphoma (NHL) are common in Asia, It's biological behavior is different from B-cell NHL.
  • This study was designed to analyse the clinical characteristics and to evaluate the effectiveness and toxicity of standard CHOP regimen in the treatment of peripheral T-cell lymphomas-unspecified (PTCL-U) according to the Revised European- American Lymphoma (REAL) classification.
  • METHODS: 106 patients with PTCL-U were treated by standard CHOP regimen with or without involved field radiotherapy from January 1997 to December 2003 in Cancer Center, Sun Yat-sen University, The clinical characteristics, response and long-term survival rates were analysed, retrospectively.
  • All the patients were treated by standard CHOP regimen plus IFRT for bulky disease.
  • 55.7% (59/106) patients were treated by chemotherapy alone and 43.3% (46/106) were treated by chemotherapy plus radiotherapy.
  • The response rate of chemotherapy alone were 69.5% (41/59) and CR rates was 44.1% (26/59).
  • Median survival times were 24 (12-36) months.
  • CONCLUSION: Long-term survival of PTCL-U treated by standard CHOP regimen were poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566653.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


94. Gutiérrez A, Rodríguez J: Frontline autologous stem cell transplantation for peripheral T-cell lymphoma. Expert Rev Hematol; 2009 Jun;2(3):255-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline autologous stem cell transplantation for peripheral T-cell lymphoma.
  • Peripheral T-cell lymphoma constitutes a heterogeneous group, with a low incidence and no standard frontline therapy.
  • The current study evaluates the use of frontline autologous stem cell transplantation in 83 peripheral T-cell lymphomas included in the first and largest prospective trial.
  • Results indicate that the procedure is feasible, with a low treatment-related mortality, and is associated with a better outcome than obtained with conventional chemotherapy.
  • A general problem in this and other prospective trials is that approximately 30% of cases do not receive transplantation owing to disease progression.
  • For chemoresistant or relapsing patients, promising results have been reported using allogeneic stem cell transplantation or adding new agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • (PMID = 21082967.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Savage KJ: Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2008;:280-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and primary therapy in peripheral T-cell lymphomas.
  • Peripheral NK/T-cell neoplasms are an uncommon group of diseases that show distinct racial and geographic variation.
  • The prognostic significance of the T-cell phenotype has been clearly defined in recent studies by using modern lymphoma classification systems.
  • However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic gammadelta T-cell lymphomas).
  • Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.
  • Given disease rarity and biological heterogeneity, advances in diagnosis, prognosis and treatment have lagged behind DLBCL.
  • Recently, however, studies are emerging that focus specifically on PTCLs with the ultimate goal of better understanding disease biology and developing more effective therapies.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074097.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone
  •  go-up   go-down


96. Rodríguez J, Gutiérrez A, Martínez-Delgado B, Perez-Manga G: Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol; 2009 Sep;71(3):181-98
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
  • Prognosis of PTCL is generally poor when treated with conventional chemotherapy regimens used in B-cell aggressive lymphomas.
  • Recent advances in genomic and molecular profiling of PTCL have allowed to further insight this heterogeneous group of neoplasias and their main prognostic factors.
  • This review will try to summarize the main clinical problems related to standard frontline and salvage therapy, including the use of conventional chemotherapy and high-dose, dose-dense and immunotherapeutic strategies, as well as new approaches based on biological knowledge and the use of new drugs or immunotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / antagonists & inhibitors. Drug Delivery Systems / trends. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Chromosome Aberrations. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics / methods. Humans. Immunotherapy / methods. Immunotherapy / trends. Neoplasm Invasiveness. Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056295.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 146
  •  go-up   go-down


97. Nademanee A: Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol; 2009 Aug;2(4):425-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation for non-Hodgkin lymphoma.
  • High-dose therapy followed by autologous hematopoietic stem cell transplantation (auto-HCT) has become the treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma (NHL).
  • However, relapse remains the most common cause of treatment failure after auto-HCT.
  • More intensive regimens incorporating radioimmunotherapy into high-dose regimens have been developed to prevent relapse.
  • The role of auto-HCT for follicular lymphoma and mantle cell lymphoma remain inconclusive.
  • Since prognosis of patients with peripheral T-cell lymphoma, not otherwise specified are very poor with conventional chemotherapy, auto-HCT during first remission is being explored in peripheral T-cell lymphoma.
  • Reduced-intensity conditioning followed by allo-HCT has been shown to reduce transplant-related mortality but graft-versus-host disease continues to be the major problem, thus the role of allo-HCT in NHL remains an investigational approach for NHL.
  • The outcomes of auto-HCT and allo-HCT for various lymphomas are reviewed.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Humans


98. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • First-line chemotherapy was mostly CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisolone)-based and complete response (CR) was achieved in 25% of patients.
  • Interestingly, OS did not differ whether chemotherapy regimens contained anthracycline or not.
  • Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Taiwan / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Perez K, Castillo J, Dezube BJ, Pantanowitz L: Human Immunodeficiency Virus-associated anaplastic large cell lymphoma. Leuk Lymphoma; 2010 Mar;51(3):430-8
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human Immunodeficiency Virus-associated anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) is a distinct subtype of peripheral T-cell lymphoma (PTCL) characterized by the expression of CD30 in lymphoma cells.
  • Like aggressive B-cell non-Hodgkin lymphoma, the risk of developing PTCL is also increased in the setting of HIV infection.
  • Analysis of these cases showed that this group of HIV-infected patients was on average 38 years of age with a male-to-female ratio of 4:1, and a reported median CD4 cell count of 83 cells/mm(3).
  • HIV-associated ALCL cells rarely expressed anaplastic lymphoma kinase.
  • These lymphomas manifested almost exclusively with extranodal involvement and exhibited a very aggressive clinical course.
  • The administration of chemotherapy and early stages at presentation were identified as good prognostic factors, while the use of HAART showed a statistical trend toward improved survival in HIV-associated ALCL.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / virology


100. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B: Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol; 2009 Jun;20(6):1080-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.
  • BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined.
  • Clinical characteristics and treatment results were reviewed.
  • RESULTS: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy.
  • Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients.
  • Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR.
  • Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain.
  • CONCLUSION: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2000 Mar;85(3):256-62 [10702813.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):459-63 [10716161.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] Pathol Int. 2006 Nov;56(11):668-73 [17040289.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):220-2 [15699701.001]
  • [Cites] Pediatr Dev Pathol. 1999 Sep-Oct;2(5):478-83 [10441626.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):983-92 [9486591.001]
  • [Cites] Am J Clin Pathol. 2000 Apr;113(4):487-96 [10761449.001]
  • [Cites] Leukemia. 2000 Jun;14(6):991-7 [10865963.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):1027-32 [10895827.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):285-96 [11224598.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):41-50 [11447750.001]
  • [Cites] Am J Clin Pathol. 2001 Sep;116(3):410-9 [11554170.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):243-51 [11807981.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):253-8 [11957154.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):531-3 [12688327.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):233-43 [12876672.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] Blood. 1990 Jun 1;75(11):2213-9 [2140703.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):161-4 [7536454.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1453-5 [8751461.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):495-500 [8882963.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):781-90 [9236834.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1367-72 [9264394.001]
  • (PMID = 19237479.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4092251
  •  go-up   go-down






Advertisement